Substituted pyridazinones as herbicides

By preparing and using phenyl-pyridazin-dione and phenyl-pyridazinone derivatives of formula (I), the problem of poor efficacy of existing herbicides in controlling broadleaf dicotyledonous weeds was solved, and effective weed control was achieved.

CN114555563BActive Publication Date: 2024-11-15SYNGENTA CROP PROTECITON AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080051179.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-18
Filing Date
2020-07-17
Publication Date
2024-11-15
Estimated Expiration
2040-07-17

AI Technical Summary

Technical Problem

Existing herbicides are ineffective in controlling broadleaf dicotyledonous weeds, and there is a lack of effective compounds and compositions.

Method used

Substituted phenyl-pyridazin-dione and phenyl-pyridazinone derivatives having formula (I) are provided for the preparation of herbicidal compositions by which unwanted plant growth, particularly broadleaf dicotyledonous weeds, is controlled by these compounds.

Benefits of technology

It exhibited surprisingly good herbicidal activity, effectively controlling the growth of broadleaf dicotyledonous weeds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003470090860000031
    Figure BDA0003470090860000031
  • Figure BDA0003470090860000041
    Figure BDA0003470090860000041
  • Figure BDA0003470090860000062
    Figure BDA0003470090860000062
Patent Text Reader

Abstract

The present invention relates to substituted phenyl-pyridazine-dione and substituted phenyl-pyridazinone derivatives of herbicides of formula (I), and methods and intermediates for preparing such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, and the use of such compounds and compositions for controlling undesirable plant growth in crops of useful plants: in particular the use of controlling weeds such as broad-leaved dicotyledonous weeds.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to herbicidal substituted phenyl-pyridazine-dione and substituted phenyl-pyridazinone derivatives of formula (I), as well as processes and intermediates for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, and to the use of such compounds and compositions for controlling undesirable vegetation in crops of useful plants: in particular for controlling weeds such as broad-leaved dicotyledonous weeds.

[0002] The herbicide pyridazinones are known from WO 2009 / 086041. Furthermore, herbicidal 5- / 6-membered heterocyclyl-substituted pyridazinones are known from WO 2011 / 045271. Meanwhile WO 2013 / 160126 describes indolyl-pyridazinones derivatives which exhibit herbicidal activity.

[0003] The present invention is based on the finding that substituted phenyl-pyridazine-diones and substituted phenyl-pyridazinone derivatives of the formula (I) exhibit unexpectedly good herbicidal activity.

[0004] Therefore, in a first aspect, there is provided a compound having formula (I)

[0005] or a salt or N-oxide thereof, wherein

[0006] R 1 Selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 alkoxy, C1-C2 alkoxy-C1-C2 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, cyano-C1-C4 alkyl, C2-C4 haloalkenyl, C2-C4 alkynyl and C2-C4 haloalkynyl;

[0007] R 2 Selected from the group consisting of: hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C6 alkoxy, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C1-C6 hydroxyalkyl-, C1-C6 alkylcarbonyl-, -S(O) m C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, -C(C1-C3 alkyl)=NO-C1-C3 alkyl and C2-C6 haloalkynyl;

[0008] G is hydrogen or C(O)R 3 ;

[0009] R 3 Selected from the group consisting of: C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-S-, C1-C6 alkoxy, -NR 4 R 5 and optionally one or more R 6 Substituted phenyl;

[0010] R 4 and R 5 are each independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl, or R 4 and R 5 together can form a morpholinyl ring; and,

[0011] R 4a and R 5a are each independently selected from the group consisting of C1-C6 alkoxy and C3-C6 cycloalkyl, or R 4a and R 5a together can form a morpholinyl ring; and,

[0012] R 6 Selected from the group consisting of halogen, cyano, nitro, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy and C1-C3 haloalkoxy;

[0013] X and Y are each independently hydrogen, C1-C3 alkyl, cyclopropyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, or halogen;

[0014] D is a substituted monocyclic heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, substituted on at least one ring carbon atom by R 8 and / or substituted on at least one ring nitrogen atom by R 9 replace;

[0015] At least one R 8 Selected from the group consisting of: C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, -NR 4a R5a 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino ... 3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0016] At least one R 9 Selected from the group consisting of: C5-C6 alkyl, C5-C6 haloalkyl, C3-C6-cycloalkyl, C1-C3 alkoxy-C3 alkyl-, C3 alkoxy-C1-C2 alkyl-, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C1-C6 hydroxyalkyl-, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0017] m is an integer of 0, 1 or 2;

[0018] Each R 16are independently halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;

[0019] or D is occupied by at least one R 8 Substituted phenyl ring;

[0020] and,

[0021] W is

[0022]

[0023] in:

[0024] "a" represents the point of attachment to the phenyl-pyridazinedione / phenyl-pyridazinone moiety,

[0025] "b" indicates the point of attachment to ring D,

[0026] R 10 , R 12 , R 14 and R 15 Each is independently hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;

[0027] or R 10 and R 12 Together with the carbon atoms to which they are attached, they form a C3-C6 carbocyclic ring; and

[0028] R 11 and R 13 are each independently hydrogen, halogen, C1-C3 alkyl, or C1-C3 haloalkyl;

[0029] The premise is that when R 11 or R 13 When one of them is halogen, C1-C3 alkyl or C1-C3 haloalkyl, the other is hydrogen.

[0030] In a second aspect, there is provided a compound having formula (I)

[0031]

[0032] or a salt or N-oxide thereof, wherein

[0033] R 1 Selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 alkoxy, C1-C2 alkoxy-C1-C2 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, cyano-C1-C4 alkyl, C2-C4 haloalkenyl, C2-C4 alkynyl and C2-C4 haloalkynyl;

[0034] R 2Selected from the group consisting of: hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C6 alkoxy, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C1-C6 hydroxyalkyl-, C1-C6 alkylcarbonyl-, -S(O) m C1-C6 alkyl, -NR 4 R 5 , -C(C1-C3 alkyl)=N-O-C1-C3 alkyl and C2-C6 haloalkynyl;

[0035] G is hydrogen or C(O)R 3 ;

[0036] R 3 Selected from the group consisting of: C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-S-, C1-C6 alkoxy, -NR 4 R 5 and optionally one or more R 6 Substituted phenyl;

[0037] R 4 and R 5 are each independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl, or R 4 and R 5 together can form a morpholinyl ring; and,

[0038] R 6 Selected from the group consisting of halogen, cyano, nitro, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy and C1-C3 haloalkoxy;

[0039] X is cyclopropyl (preferably, X is in the ortho position relative to the pyridazinone / pyridazine-dione moiety);

[0040] Y is hydrogen, C1-C3 alkyl, cyclopropyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, or halogen (with respect to the -WD moiety, Y is in the ortho position (3 position));

[0041] D is a substituted or unsubstituted monocyclic heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein when D is substituted, it is replaced on at least one ring carbon atom by R 8 substituted and / or on the ring nitrogen atom by R 9replace;

[0042] Each R 8 are independently oxygen, hydroxy, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl-, C1-C6 alkylcarbonyl-, C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, NR 4 R 5 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5, C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino ... 3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0043] m is an integer of 0, 1 or 2 (preferably 0 or 2); and

[0044] Each R 9 are independently C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C1-C6 hydroxyalkyl-, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0045] Each R 16 are independently halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;

[0046] or D is a substituted or unsubstituted phenyl ring, and wherein when the phenyl ring is substituted, it is replaced by 1 to 5 R 8 replace;

[0047] And, W is

[0048] in

[0049] "a" represents the point of attachment to the phenyl-pyridazinedione / phenyl-pyridazinone moiety,

[0050] "b" indicates the point of attachment to ring D,

[0051] R 10 , R 12 , R 14 and R 15 Each is independently hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;

[0052] or R 10 and R 12 Together with the carbon atoms to which they are attached, they form a C3-C6 carbocyclic ring; and

[0053] R 11 and R 13 are each independently hydrogen, halogen, C1-C3 alkyl, or C1-C3 haloalkyl;

[0054] The premise is that when R 11 or R 13 When one of them is halogen, C1-C3 alkyl or C1-C3 haloalkyl, the other is hydrogen.

[0055] In a third aspect, there is provided a compound having formula (I)

[0056]

[0057] or a salt or N-oxide thereof, wherein

[0058] R 1 Selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 alkoxy, C1-C2 alkoxy-C1-C2 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, cyano-C1-C4 alkyl, C2-C4 haloalkenyl, C2-C4 alkynyl and C2-C4 haloalkynyl;

[0059] R 2 Selected from the group consisting of: hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C6 alkoxy, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C1-C6 hydroxyalkyl-, C1-C6 alkylcarbonyl-, -S(O) m C1-C6 alkyl, -NR 4 R 5, -C(C1-C3 alkyl)=N-O-C1-C3 alkyl and C2-C6 haloalkynyl;

[0060] G is hydrogen or C(O)R 3 ;

[0061] R 3 Selected from the group consisting of: C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-S-, C1-C6 alkoxy, -NR 4 R 5 and optionally one or more R 6 Substituted phenyl;

[0062] R 4 and R 5 are each independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl, or R 4 and R 5 together can form a morpholinyl ring; and,

[0063] R 6 Selected from the group consisting of halogen, cyano, nitro, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy and C1-C3 haloalkoxy;

[0064] X is hydrogen, C1-C3 alkyl, cyclopropyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, or halogen (preferably, X is in the ortho position relative to the pyridazinone / pyridazine-dione moiety);

[0065] Y is cyclopropyl (preferably, Y is in the ortho position relative to the -WD moiety);

[0066] D is a substituted or unsubstituted monocyclic heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein when D is substituted, it is replaced on at least one ring carbon atom by R 8 substituted and / or on the ring nitrogen atom by R 9 replace;

[0067] Each R 8are independently oxygen, hydroxy, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl-, C1-C6 alkylcarbonyl-, C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, NR 4 R 5 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino ... 3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0068] m is an integer of 0, 1 or 2; and

[0069] Each R 9 are independently C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C1-C6 hydroxyalkyl-, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0070] Each R 16 are independently halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;

[0071] or D is a substituted or unsubstituted phenyl ring, and wherein when the phenyl ring is substituted, it is replaced by 1 to 5 R 8 replace; and,

[0072] W is

[0073] in

[0074] "a" represents the point of attachment to the phenyl-pyridazinedione / phenyl-pyridazinone moiety,

[0075] "b" indicates the point of attachment to ring D,

[0076] R 10 , R 12 , R 14 and R 15 Each is independently hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;

[0077] or R 10 and R 12 Together with the carbon atoms to which they are attached, they form a C3-C6 carbocyclic ring;

[0078] R 11 and R 13 are each independently hydrogen, halogen, C1-C3 alkyl, or C1-C3 haloalkyl;

[0079] The premise is that when R11 or R 13 When one of them is halogen, C1-C3 alkyl or C1-C3 haloalkyl, the other is hydrogen.

[0080] Compounds of formula (I) may contain asymmetric centers and may exist as single enantiomers, in pairs of enantiomers in any ratio, or where there are more than one asymmetric center, containing all possible ratios of diastereomers. Typically, one of the enantiomers has an enhanced biological activity compared to the other possibilities.

[0081] Similarly, where disubstituted olefins are present, these may be present in the E or Z form or as a mixture of the two in any ratio.

[0082] In addition, compounds of formula (I) may be in equilibrium with alternative tautomeric forms. For example, compounds of formula (Ii), i.e., compounds of formula (I) wherein R 2 is hydrogen and G is hydrogen), can be drawn in at least three tautomeric forms:

[0083]

[0084] It should be appreciated that all tautomeric forms (single tautomers or mixtures thereof), racemic mixtures and individual isomers are included within the scope of the present invention.

[0085] Each alkyl moiety, alone or as part of a larger group (such as alkoxy, alkylthio, alkoxycarbonyl, alkylcarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl, etc.), can be straight or branched. Typically, the alkyl is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, or n-hexyl. Alkyl is typically C1-C6 alkyl (except when already more narrowly defined), but is preferably C1-C4 alkyl or C1-C3 alkyl, and more preferably C1-C2 alkyl (such as methyl).

[0086] Alkenyl and alkynyl moieties may be in straight or branched form, and these alkenyl moieties may be of (E)- or (Z)-configuration as appropriate. Alkenyl or alkynyl moieties are typically C2-C4 alkenyl or C2-C4 alkynyl, more specifically vinyl, allyl, ethynyl, propargyl or prop-1-ynyl. Alkenyl and alkynyl moieties may contain one or more double and / or triple bonds in any combination; but preferably contain only one double bond (for alkenyl) or only one triple bond (for alkynyl).

[0087] Preferably, the term cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0088] In the context of the present specification, the term "aryl" preferably means phenyl. As used herein, the term "heteroaryl" means an aromatic ring system comprising at least one ring heteroatom and consisting of a monocyclic ring. Preferably, the monocyclic ring will contain 1, 2 or 3 ring heteroatoms independently selected from nitrogen, oxygen and sulfur. Typically, "heteroaryl" is furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, or 1,3,5-triazinyl.

[0089] Heterocyclyl and heterocycle (alone or as part of a larger group (e.g. heterocyclyl-alkyl-)) are ring systems containing at least one heteroatom and can be in monocyclic or bicyclic form. Preferably, the heterocyclyl will contain up to two heteroatoms, which are preferably selected from nitrogen, oxygen and sulfur. Examples of heterocyclic groups include oxetane, thietane, azetane and 7-oxa-bicyclo [2.2.1] hept-2-yl. Heterocyclyl containing a single oxygen atom as a heteroatom is most preferred. The heterocyclyl is preferably 3 to 8, more preferably 3 to 6 monocyclic, and can be fully saturated or partially saturated.

[0090] Halogen (or halo) encompasses fluorine, chlorine, bromine or iodine. The halogen is applied correspondingly to the halogen in other definition contexts, such as haloalkyl or halophenyl.

[0091] Haloalkyl having a chain length of from 1 to 6 carbon atoms is, for example, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, 2-chloroethyl, pentafluoroethyl, 1,1-difluoro-2,2,2-trichloroethyl, 2,2,3,3-tetrafluoroethyl and 2,2,2-trichloroethyl, heptafluoro-n-propyl and perfluoro-n-hexyl.

[0092] Alkoxy preferably has a chain length of from 1 to 6 carbon atoms. Alkoxy is, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy or pentyloxy or hexyloxy isomers, preferably methoxy and ethoxy. It should also be understood that two alkoxy substituents can be present on the same carbon atom.

[0093] Haloalkoxy is, for example, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2,2-difluoroethoxy or 2,2,2-trichloroethoxy, preferably difluoromethoxy, 2-chloroethoxy or trifluoromethoxy.

[0094] C1-C6Alkyl-S-(alkylthio) is, for example, methylthio, ethylthio, propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio or tert-butylthio, preferably methylthio or ethylthio.

[0095] C1-C6Alkyl-S(O)-(alkylsulfinyl) is, for example, methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, isobutylsulfinyl, sec-butylsulfinyl or tert-butylsulfinyl, preferably methylsulfinyl or ethylsulfinyl.

[0096] C1-C6Alkyl-S(O)2-(alkylsulfonyl) is, for example, methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl or tert-butylsulfonyl, preferably methylsulfonyl or ethylsulfonyl.

[0097] Group Q

[0098] Referred to herein as a pyridazinedione / pyridazinone moiety, wherein B represents the point of attachment to the remainder of the molecule (ie, to the optionally substituted phenyl-WD moiety).

[0099] The present invention also includes acceptable salts in agronomy, and compounds with formula (I) can form these salts with amine (for example ammonia, dimethylamine and triethylamine), alkali metal and alkaline earth metal alkali or quaternary ammonium salt alkali. Among alkali metal and alkaline earth metal hydroxides, oxides, alcoholates and bicarbonates and carbonates used as salt-forming substances, it is emphasized that hydroxides, alcoholates, oxides and carbonates of lithium, sodium, potassium, magnesium and calcium, but especially those of sodium, magnesium and calcium. Corresponding trimethyl sulfonium salts can also be used. Compounds with formula (I) according to the present invention also include the hydrate that can form during salt formation.

[0100] R 1 , R 2 , R 3 , R 4 , R 5 , R 4a , R 5a , R 6 , R 8 , R 9 , R 10 , R11 , R 12 , R 13 , R 14 , R 15 , R 16 The preferred values ​​of W, D, Dp, G, X, Y and m are as listed below, and compounds with formula (I) according to the present invention may include any combination of said values. It will be appreciated by the skilled person that the values ​​for the embodiments of any given group may be combined with the values ​​for the embodiments of any other group, wherein such combinations are not mutually exclusive.

[0101] Preferably, R 1 is selected from the group consisting of methyl, ethyl, propyl (particularly n-propyl or cyclopropyl), propargyl or C1 haloalkyl. More preferably, R 1 is methyl, ethyl, cyclopropyl, propargyl or C1 fluoroalkyl. Still more preferably, R 1 is methyl, ethyl, cyclopropyl or propargyl. Most preferably, R 1 It's methyl.

[0102] Preferably, R 2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C3 alkoxy-C1-C3 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl and C2-C6 haloalkynyl. More preferably, R 2 is selected from the group consisting of chloro, fluoro, methyl, ethyl, cyclopropyl, trifluoromethyl and methoxymethyl; more preferably, chloro, cyclopropyl, trifluoromethyl or methyl; most preferably, chloro or methyl. In one embodiment of the present invention, R 2 In another embodiment, R 2 is cyclopropyl; in a third group of embodiments, R 2 is methyl, in the fourth embodiment, R 2 is trifluoromethyl, and in a fifth group of embodiments, R 2 It's chlorine.

[0103] As used herein, G may be hydrogen or -C(O)-R 3 , and R 3 Selected from the group consisting of: C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-S-, C1-C6 alkoxy, -NR 4 R 5 and optionally one or more R 6 Substituted phenyl.

[0104] As defined herein, R 4 and R5 are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl, or they may together form a morpholinyl ring. 3 ), R 4 and R 5 are preferably each independently selected from the group consisting of methyl, ethyl, propyl, methoxy, ethoxy and propoxy and may be referred to as R 34 and R 35 In other substituents (such as R 2 , R 8 ), R 4 and R 5 are preferably each independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy, or C3-C6 cycloalkyl, and may be referred to as R 84 and R 85 In more than one R 4 When contained within a larger moiety, such as in the group -NR 4 C(O)NR 4 R 5 The skilled person will understand that each R 4 are independent, and therefore in such a section, the two R 4 The groups may be identical or they may be different from each other.

[0105] R 6 is selected from the group consisting of halogen, cyano, nitro, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy and C1-C3 haloalkoxy. 6 Selected from the group consisting of halogen, C1-C3 alkyl and C1-C3 haloalkyl.

[0106] Preferably, R 3 is C1-C4 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -C1-C4 alkoxy, -NR 4 R 5 (where R 4 and R 5 More preferably, R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl, methoxy, ethoxy or tert-butoxy. More preferably, R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl or methoxy.

[0107] In one group of embodiments, G is hydrogen or -C(O)-R 3 , where R 3is C1-C4 alkyl, C2-C3 alkenyl, C2-C3 alkynyl or -C1-C4 alkoxy. In another embodiment, G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl or methoxy. However, it is particularly preferred that G is hydrogen, or -C(O)-R 3 , where R 3 It is isopropyl.

[0108] When Y is cyclopropyl, X is preferably hydrogen, cyclopropyl, halogen or C1 haloalkyl, more preferably hydrogen, fluorine, chlorine, bromine or C1 fluoroalkyl and also more preferably hydrogen, fluorine, chlorine or trifluoromethyl. Most preferably, when Y is cyclopropyl, X is fluorine. In one group of embodiments, it is preferred that X is in the ortho position (6 position) relative to the pyridazinone / pyridazinedione moiety (group Q). It is particularly preferred that X is fluorine, chlorine or C1-haloalkyl (particularly C1 fluoroalkyl) and is in the ortho position (6 position) relative to the pyridazinone / pyridazinedione moiety (group Q). Most preferably, X is fluorine and is in the ortho position (6 position) relative to the pyridazinone / pyridazine-dione moiety (group Q).

[0109] When X is cyclopropyl, Y is preferably hydrogen, C1-C3 alkyl, cyclopropyl, C1-C3 haloalkyl or halogen, and more preferably in such embodiments Y is hydrogen, chlorine, fluorine, or bromine. Most preferably, when X is cyclopropyl, Y is chlorine.

[0110] In one set of embodiments, it is preferred that Y is in the ortho position (position 3) relative to the -WD moiety. In another set of embodiments, Y is in the para position relative to the pyridazinone / pyridazinedione moiety (group Q).

[0111] It is particularly preferred that Y is in the ortho position (3 position) relative to the -WD moiety and is halogen, especially chlorine or fluorine; more preferably chlorine.

[0112] As described herein, D is a substituted or unsubstituted phenyl ring (Dp) or a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl ring comprising 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein when D is a substituted heteroaryl ring or a substituted phenyl ring, it is replaced on at least one ring carbon atom by R 8 Substitution and / or in the case of heteroaryl rings on the ring nitrogen atoms by R 9When D is a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl ring, it is preferably a substituted (as described herein) or unsubstituted furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyridyl, pyridonyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl or 1,3,5-triazinyl ring.

[0113] In such embodiments, D is preferably a substituted (as described herein) or unsubstituted pyridinyl, pyrazolyl, thiazolyl, pyrimidinyl, thienyl, triazolyl or oxadiazolyl ring, and more preferably a pyridinyl ring.

[0114] In one group of embodiments, D is a substituted (as described herein) or unsubstituted pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyridonyl, pyrimidinyl, pyridazinyl, or pyrazinyl ring.

[0115] In another group of such embodiments, D is a substituted (as described herein) or unsubstituted oxazolyl, thiazolyl, or pyridinyl ring. In certain embodiments, D is a substituted or unsubstituted pyridinyl ring, or a substituted or unsubstituted thiazolyl ring.

[0116] D is R 8 Substitution will depend on the presence or absence of cyclopropyl at position X and / or position Y. However, in general, when D is a substituted 5 or 6 membered heteroaryl ring, it is preferably substituted by 1 or 2 R 8 and / or 1 R 9 , more preferably 1 or 2 R 8 When D is a 5-membered substituted heteroaryl ring, it is most preferably substituted with 1 R 8 When D is a substituted phenyl ring, it is preferably substituted with 1 or 2 R 8 , more preferably 1 R 8 replace.

[0117] When at least one of X and Y is cyclopropyl and D is substituted, each R 8may be independently selected from hydrogen, oxygen, hydroxyl, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl-, C1-C6 alkylcarbonyl-, C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, NR 4 R 5 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, -NR 4 C(O)NR 4 R 5, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl(C1-C6 alkyl)amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl(C1-C6 alkyl)amino-, C3-C6 cycloalkylsulfonylamino-, C3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0118] m is an integer of 0, 1 or 2 (preferably 0 or 2); and each R 9 are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C1-C6 hydroxyalkyl-, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0119] Each R 16 are independently halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.

[0120] When both X and Y are not cyclophenyl and D is a phenyl ring, D will be replaced by at least one R selected from the group consisting of 8 Substitution: C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m-C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, -NR 4a R 5a 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino ... 3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 Substitution; wherein m, R 4 , R 5 and R 16 is as defined herein.

[0121] As defined herein, in the case where both X and Y are not cyclopropyl, R 4a and R 5a are each independently selected from the group consisting of C1-C6 alkoxy and C3-C6 cycloalkyl, or R 4 and R 5 Together they can form a morpholinyl ring.

[0122] Any additional R 8The substituents may be selected from the group consisting of oxygen, hydroxyl, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl-, C1-C6 alkylcarbonyl-, C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, NR 4 R 5 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, -NR 4 C(O)NR 4 R 5, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl(C1-C6 alkyl)amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl(C1-C6 alkyl)amino-, C3-C6 cycloalkylsulfonylamino-, C3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 Substitution; wherein m, R 4 , R 5 and R 16 is as defined herein.

[0123] When both X and Y are not cyclophenyl and D is a monocyclic heteroaryl ring, D will be replaced on a ring carbon with at least one R selected from the group consisting of 8 Substitution: C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, NR 4a R 5a 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5, C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino ... 3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 and / or D will be replaced on the ring nitrogen by at least one R selected from the group consisting of 9 Substitution: C5-C6 alkyl, C5-C6 haloalkyl, C3-C6-cycloalkyl, C1-C3 alkoxy-C3 alkyl-, C3 alkoxy-C1-C2 alkyl-, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C1-C6 hydroxyalkyl-, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 Substitution; wherein m, R 4 , R 5 , R 4a , R 5a and R 16 is as defined herein.

[0124] In such embodiments where both X and Y are not cyclopropyl, any additional ring carbon R 8The substituents may be selected from the group consisting of oxygen, hydroxyl, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl-, C1-C6 alkylcarbonyl-, C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, -NR 4 R 5 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino ... 3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 Substitution; wherein m, R4 , R 5 and R 16 is as defined herein, and / or any additional ring nitrogen R 9 The substituent may be selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C1-C6 hydroxyalkyl-, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 Substitution; wherein m, R 4 , R 5 and R 16 is as defined herein.

[0125] In embodiments where at least one of X and Y is cyclopropyl, each R 8 Preferably, each R is independently oxo, C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, amino, -NHC(O)CH3, hydroxyl, C1-C4 alkoxy, or C1-C4 alkylthio. More preferably, each R 8 is independently oxo, C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy, C1-C4 alkoxy or C1-C4 alkylthio. Most preferably, each R 8 are independently halogen, or C1-C4 haloalkyl.

[0126] In embodiments where at least one of X and Y is cyclopropyl, each R 9 Preferably, they are independently C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, or C1-C4 alkylthio.

[0127] In certain embodiments where at least one of X and Y is cyclopropyl and D is a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl ring as described above, D is selected from the group consisting of 4-chloro-3-pyridyl, 4-trifluoromethylpyridyl, 3-pyridyl, and 2-chloro-thiazol-5-yl, 2-chloro-3-pyridyl, 3-chloro-4-pyridyl, 1-methyl-3-(trifluoromethyl)-pyrazol-4-yl, thiazol-2-yl, thiazol-5-yl, pyrimidin-5-yl, 4-(tert-butyloxy)phenyl, 2-chloro-4-pyridyl, 2-methyl-4-pyridyl, 2-trifluoromethyl-4-pyridinyl, 4-pyridinyl, 2-amino-4-pyridinyl, thien-3-yl, 1-methyl-pyrazol-4-yl, 2-methyl-triazol-4-yl, 5-methyl-1,3,4-oxadiazol-2-yl, 5-methyl-3-pyridinyl, 5-methyl-2-pyridinyl, 6-methyl-2-pyridinyl, 3-methyl-2-pyridinyl, 6-chloro-3-pyridinyl, 3-trifluoromethyl-3-pyridinyl, 4-methyl-2-pyridinyl, 2-acetamidothiazol-5-yl, 2-fluoro-4-pyridinyl, and 2-trifluoromethyl-3-pyridinyl. In a subset of these embodiments, D is selected from the group consisting of 4-chloro-3-pyridinyl, 4-trifluoromethylpyridinyl, 3-pyridinyl, and 2-chloro-thiazol-5-yl, 2-chloro-3-pyridinyl, 3-chloro-4-pyridinyl, 1-methyl-3-(trifluoromethyl)-pyrazol-4-yl, thiazol-2-yl, thiazol-5-yl, pyrimidin-5-yl, 4-(tert-butoxy)phenyl, 2-chloro-4-pyridinyl, 2-methyl-4-pyridinyl, 2-trifluoromethyl-4-pyridinyl, 4-pyridinyl, thien-3-yl, 5-methyl-3-pyridinyl, 5-methyl-2-pyridinyl, 6-methyl-2-pyridinyl, 3-trifluoromethyl-3-pyridinyl, 2-fluoro-4-pyridinyl, and 2-trifluoromethyl-3-pyridinyl. In a further subset of these embodiments, D is selected from the group consisting of 4-chloro-3-pyridinyl, 4-trifluoromethylpyridinyl, 3-pyridinyl, 2-fluoro-4-pyridinyl and 2-chloro-thiazol-5-yl (preferably 2-fluoro-4-pyridinyl).

[0128] When D is a phenyl ring Dp and is substituted, it may be substituted by 1 to 5 R 8 The substitution may thus be represented by the following structure:

[0129] At least one of the R 8p1 , R 8p2 , R 8p3 , R 8p4 and R 8p5 The skilled person will understand that if R 8p1 , R 8p2 , R 8p3 , R 8p4 and R8p5 If at least one of the R is not hydrogen, any remaining positions on the phenyl ring may be unsubstituted or, alternatively, carry an additional R 8 The position of the substituent on the phenyl ring is indicated by the superscript p. When Dp is unsubstituted, R 8p1 , R 8p2 , R 8p3 , R 8p4 and R 8p5 will not exist,

[0130] As mentioned above, D is R 8 The substitution will depend on the presence or absence of cyclopropyl groups at positions X and / or Y. Thus, in Dp, when at least one of X and Y is a cyclopropyl group, it is preferred that R 8p1 , R 8p2 , R 8p3 , R 8p4 and R 8p5 One or more of are independently selected from the group consisting of cyano, amino, C1-C3 dialkylamino, hydroxy, C1-C3 alkyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy and halogen, and b is the point of attachment to the rest of the molecule.

[0131] In one set of such embodiments, R 8p1 , R 8p2 , R 8p3 , R 8p4 and R 8p5 One or more of are independently selected from cyano, C1-C3 alkyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, or halogen. 8p1 , R 8p2 , R 8p3 , R 8p4 and R 8p5 One or more of are independently selected from cyano, halogen (especially chlorine or fluorine), methyl, methoxy, and trifluoromethyl.

[0132] In yet another set of embodiments, R 8p1 , R 8p2 , R 8p4 and R 8p5 Each of them does not exist, and R 8p3 is cyano, C1-C3 alkyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, or halogen. Preferably, in this group of embodiments, R 8p3 is halogen, more preferably chlorine.

[0133] In yet another set of embodiments, R 8p1 , R 8p4and R 8p5 Each of them does not exist, and R 8p2 and R 8p3 Each is independently cyano, C1-C3 alkyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, or halogen. In this group of embodiments, it is particularly preferred that R 8p2 and R 8p3 are each independently halogen, and more preferably, R 8p2 and R 8p3 It's all chlorine.

[0134] In a particularly preferred group of embodiments, when at least one of X and / or Y is a cyclopropyl group, D is an unsubstituted phenyl ring.

[0135] In another embodiment, a particularly preferred group of embodiments, when at least one of X and / or Y is cyclopropyl, D is selected from the group consisting of 4-chloro-phenyl, 4-trifluoromethyl-phenyl, 4-cyanophenyl, 4-fluoro-phenyl, 3,4-di-fluoro-phenyl, 2-trifluoromethyl-phenyl and 4-tolyl.

[0136] W acts as a linker moiety, connecting ring D to the remainder of the molecule (i.e., to the phenyl-pyridazinone / phenyl-pyridazinedione moiety). Compounds of formula (I) wherein the linker is W1 are herbicides, while compounds of formula (I) wherein the linker is W2 may not only be herbicides, but also be intermediates useful in producing compounds of formula (I) carrying a W1 linker. Thus, in one set of embodiments, W is W1, and in a second set of embodiments, W is W2. In a third set of embodiments, W is -C≡C-.

[0137] Preferably, R 10 , R 11 , R 12 and R 13 Each is independently selected from hydrogen or C1-C3 alkyl. In one embodiment, R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0138] Preferably, R 14 and R 15 Each is independently selected from hydrogen or C1-C3 alkyl. In one embodiment, R 14 and R 15 It's all hydrogen.

[0139] Specific examples of W include -CH2-CH2-, and -CH=CH-, cis and trans In a more preferred embodiment, W is -CH2-CH2-, or -CH=CH- (particularly (E)-CH=CH-), still more preferably -CH2-CH2-.

[0140] In a preferred group of embodiments (wherein both X and Y are not cyclopropyl), in compounds having formula (I):

[0141] R 1 is methyl, ethyl, cyclopropyl, propargyl or C1 fluoroalkyl;

[0142] R 2 is chloro, cyclopropyl, trifluoromethyl or methyl;

[0143] G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl, methoxy, ethoxy, or tert-butoxy;

[0144] X is fluorine, chlorine or C1-haloalkyl and is in the ortho position relative to the pyridazinone / pyridazine-dione moiety;

[0145] Y is hydrogen, chlorine, fluorine or bromine and is in the ortho position relative to the -WD moiety;

[0146] D is at least one R selected from the group consisting of 8 Substituted phenyl ring: C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, -NR 4a R 5a 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5, C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino ... 3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino and C1-C6 haloalkoxy(C1-C6 alkyl)amino, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace; and

[0147] Any additional R 8 The substituents may be selected from the group consisting of hydroxy, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C6 alkoxy, C2-C6 alkenyl and C2-C6 alkynyl;

[0148] R 4 and R 5 Each is independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy or C3-C6 cycloalkyl;

[0149] m is an integer of 0, 1 or 2 (preferably 0 or 2);

[0150] R 4a and R 5a are each independently selected from the group consisting of C1-C6 alkoxy and C3-C6 cycloalkyl, or R 4a and R 5a together can form a morpholinyl ring; and,

[0151] Each R 16 are independently halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;

[0152] W is W1; and

[0153] R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0154] In a more preferred group of embodiments (wherein both X and Y are not cyclopropyl), in compounds having formula (I):

[0155] R 1 It is methyl;

[0156] R 2 It is methyl;

[0157] G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl, methoxy, ethoxy, or tert-butoxy;

[0158] X is fluorine and is in the ortho position relative to the pyridazinone / pyridazine-dione moiety;

[0159] Y is chlorine and is in the ortho position relative to the -WD moiety;

[0160] D is 1 or 2 R 8 A substituted phenyl ring, wherein at least one R 8 Selected from the group consisting of: C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, -S(O)2NHC(O)C1-C3 alkyl, -S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl(C1-C6 alkyl)amino-, C1-C6 haloalkylcarbonylamino- and C1-C6 haloalkylcarbonyl(C1-C6 alkyl)amino-, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace; and

[0161] Any additional R 8 The substituent may be selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 haloalkyl;

[0162] R 4and R 5 Each is independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy or C3-C6 cycloalkyl;

[0163] m is 0 or 2 (preferably 0);

[0164] Each R 16 are independently halogen, cyano, C1-C4 alkyl, C1-C3 haloalkyl or C1-C4 alkoxy;

[0165] W is W1; and

[0166] R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0167] In an even more preferred group of embodiments (wherein both X and Y are not cyclopropyl), in compounds having formula (I):

[0168] R 1 It is methyl;

[0169] R 2 It is methyl;

[0170] G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl or methoxy;

[0171] X is fluorine and is in the ortho position relative to the pyridazinone / pyridazine-dione moiety;

[0172] Y is chlorine and is in the ortho position relative to the -WD moiety;

[0173] D is an R selected from the group consisting of 8 Substituted phenyl ring: -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -S(O)2NHC(O)C1-C3 alkyl, -S(O)2NR 4 R 5 , -C(O)OH, -C(O)OC1-C6 alkyl and -C(O)NR 4 R 5, or a ring system selected from the group consisting of phenyl, morpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyridyl, pyridonyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, or 1,3,5-triazinyl rings, wherein the ring system is surrounded by 0 to 2 R 16 replace;

[0174] R 4 and R 5 Each is independently hydrogen or C1-C3 alkyl;

[0175] m is 0 or 2 (preferably 0);

[0176] Each R 16 are independently halogen or C1-C4 alkyl (preferably methyl);

[0177] W is W1; and

[0178] R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0179] In yet another even more preferred group of embodiments (wherein both X and Y are not cyclopropyl), in compounds having formula (I):

[0180] R 1 It is methyl;

[0181] R 2 It is methyl;

[0182] G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl;

[0183] X is fluorine and is in the ortho position relative to the pyridazinone / pyridazine-dione moiety;

[0184] Y is chlorine and is in the ortho position relative to the -WD moiety;

[0185] D is an R selected from the group consisting of 8Substituted phenyl ring: methylsulfanylmethyl, isopropylsulfanylmethyl, sulfamoyl, methylsulfamoyl and carbamoyl, or a ring system selected from the group consisting of phenyl, morpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, 1,2,4-triazolyl, oxazolyl and thiazolyl rings, wherein the ring system is substituted by 0 to 2 R 16 replace;

[0186] Each R 16 It is methyl;

[0187] W is W1; and

[0188] R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0189] In a preferred embodiment of the substitution group wherein both X and Y are not cyclopropyl, in the compound having formula (I):

[0190] R 1 is methyl, ethyl, cyclopropyl, propargyl or C1 fluoroalkyl;

[0191] R 2 is chloro, cyclopropyl, trifluoromethyl or methyl;

[0192] G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl, methoxy, ethoxy, or tert-butoxy;

[0193] X is fluorine, chlorine or C1-haloalkyl and is in the ortho position relative to the pyridazinone / pyridazine-dione moiety;

[0194] Y is hydrogen, chlorine, fluorine or bromine and is in the ortho position relative to the -WD moiety;

[0195] D is a 5- or 6-membered monocyclic heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, which is substituted on a ring carbon with at least one R selected from the group consisting of 8 Substitution: C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m-C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, NR 4a R 5a 、-C(S)NR 4 R 5 、-S(O)2NHC(O)C1-C3alkyl、-S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylcarbonylamino-, C1-C6 haloalkylcarbonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino-, C1-C6 haloalkylsulfonylamino-, C1-C6 haloalkylsulfonyl (C1-C6 alkyl) amino-, C3-C6 cycloalkylsulfonylamino-, C1-C6 alkylsulfonyl (C1-C6 alkyl) amino ... 3-C6 cycloalkylsulfonyl(C1-C6 alkyl)amino-, hydroxyamino-, hydroxy(C1-C6 alkyl)amino, C1-C6 alkoxyamino, C1-C6 alkoxy(C1-C6 alkyl)amino, C1-C6 haloalkoxyamino, C1-C6 haloalkoxy(C1-C6 alkyl)amino, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace; and

[0196] Any additional R 8 The substituents may be selected from the group consisting of hydroxy, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6-cycloalkyl, C1-C6 alkoxy, C2-C6 alkenyl and C2-C6 alkynyl; and / or D will be replaced on the ring nitrogen by at least one R selected from the group consisting of 9 Substitution: C5-C6 alkyl, C5-C6 haloalkyl, C3-C6-cycloalkyl, C1-C3 alkoxy-C3 alkyl-, C3 alkoxy-C1-C2 alkyl-, C1-C3 haloalkoxy-C1-C3 alkyl-, C1-C3 alkoxy-C1-C3 alkoxy-C1-C3 alkyl-, C1-C6 hydroxyalkyl-, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m-C3-C6 cycloalkyl, cyano-C1-C6-alkyl-, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0197] R 4 and R 5 Each is independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy or C3-C6 cycloalkyl;

[0198] m is an integer of 0, 1 or 2 (preferably 0 or 2);

[0199] R 4a and R 5a are each independently selected from the group consisting of C1-C6 alkoxy and C3-C6 cycloalkyl, or R 4a and R 5a together can form a morpholinyl ring; and,

[0200] Each R 16 are independently halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy;

[0201] W is W1; and

[0202] R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0203] In a more preferred embodiment of the substitution group (wherein both X and Y are not cyclopropyl), in the compound having formula (I):

[0204] R 1 It is methyl;

[0205] R 2 It is methyl;

[0206] G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl, methoxy, ethoxy, or tert-butoxy;

[0207] X is fluorine and is in the ortho position relative to the pyridazinone / pyridazine-dione moiety;

[0208] Y is chlorine and is in the ortho position relative to the -WD moiety;

[0209] D is a 5- or 6-membered monocyclic heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, which is substituted on a ring carbon with 1 or 2 R 8Substituted, wherein at least one R 8 Selected from the group consisting of: C1-C6 haloalkylcarbonyl-, C3-C6 cycloalkylcarbonyl-, -S(O) m -C1-C6 haloalkyl, -S(O) m -C3-C6 cycloalkyl, -OS(O)2C1-C3 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, -S(O)2NHC(O)C1-C3 alkyl, -S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6 alkyl、-C(O)NHS-(O)2C1-C6 alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl(C1-C6 alkyl)amino-, C1-C6 haloalkylcarbonylamino- and C1-C6 haloalkylcarbonyl(C1-C6 alkyl)amino-, or a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace; and

[0210] Any additional R 8 The substituents may be selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 haloalkyl; and / or D will be replaced on the ring nitrogen by an R selected from the group consisting of 9 Substitution: C5-C6 alkyl, C5-C6 haloalkyl, C3-C6-cycloalkyl, -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -C1-C3 alkyl-S(O) m -C1-C6 haloalkyl, -C1-C3 alkyl-S(O) m -C3-C6 cycloalkyl, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace;

[0211] R 4 and R 5 Each is independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy or C3-C6 cycloalkyl;

[0212] m is 0 or 2 (preferably 0);

[0213] Each R 16 are independently halogen, cyano, C1-C4 alkyl, C1-C3 haloalkyl or C1-C4 alkoxy;

[0214] W is W1; and

[0215] R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0216] In an even more preferred embodiment of the alternative group wherein both X and Y are not cyclopropyl, in the compound having formula (I):

[0217] R 1 It is methyl;

[0218] R 2 It is methyl;

[0219] G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl or methoxy;

[0220] X is fluorine and is in the ortho position relative to the pyridazinone / pyridazine-dione moiety;

[0221] Y is chlorine and is in the ortho position relative to the -WD moiety;

[0222] D is a 5- or 6-membered monocyclic heteroaryl ring containing 1, 2 or 3 nitrogen atoms, which is substituted on a ring carbon with an R selected from the group consisting of 8 Substitution: -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -S(O)2NHC(O)C1-C3 alkyl, -S(O)2NR 4 R 5 , -C(O)OH, -C(O)OC1-C6 alkyl and -C(O)NR 4 R 5, or a ring system selected from the group consisting of phenyl, morpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyridyl, pyridonyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, or 1,3,5-triazinyl rings, wherein the ring system is surrounded by 0 to 2 R 16 and / or D will be replaced on the ring nitrogen by an R selected from the group consisting of 9 Substituted: C5-C6 alkyl, C3-C6-cycloalkyl, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring, and a 3-6 membered heterocyclyl ring, wherein the ring system is replaced by 0 to 2 R 16 replace;

[0223] R 4 and R 5 Each is independently hydrogen or C1-C3 alkyl;

[0224] m is 0 or 2 (preferably 0);

[0225] Each R 16 are independently halogen or C1-C4 alkyl (preferably methyl);

[0226] W is W1; and

[0227] R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0228] In yet an even more preferred embodiment of the alternative group wherein both X and Y are not cyclopropyl, in the compound having formula (I):

[0229] R 1 It is methyl;

[0230] R 2 It is methyl;

[0231] G is hydrogen or -C(O)-R 3 , where R 3 is isopropyl;

[0232] X is fluorine and is in the ortho position relative to the pyridazinone / pyridazine-dione moiety;

[0233] Y is chlorine and is in the ortho position relative to the -WD moiety;

[0234] D is replaced on a ring carbon by an R selected from the group consisting of 8 Substituted pyrazolyl or pyridyl: methylsulfanylmethyl, isopropylsulfanylmethyl, sulfamoyl, methylsulfamoyl and carbamoyl, or a ring system selected from the group consisting of phenyl, morpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, 1,2,4-triazolyl, oxazolyl and thiazolyl rings, wherein the ring system is surrounded by 0 to 2 R 16 and / or D will be replaced on the ring nitrogen by an R selected from cyclopropyl or phenyl 9 replace;

[0235] Each R 16 It is methyl;

[0236] W is W1; and

[0237] R 10 , R 11 , R 12 and R 13 It's all hydrogen.

[0238] The following Tables A-1, A-2, A-3, A-4, B-1, B-2, B-3, B-4, C-1, C-2, C-3 and C-4 illustrate specific examples of the compounds having formula (I) of the present invention.

[0239] Herbicidal compounds of the present invention. The numbering system used to describe the positions of X and Y in the compounds of formula (I) shown below is shown for clarity only.

[0240]

[0241] Table A-1 provides 672 compounds A-1.001 to A-1.672 of formula (I), wherein G is -H, W is -CH2-CH2-, and R 1 , R 2 , X, Y, and D are defined as in Table 1 below for compound numbers 1.001 to 1.672, respectively.

[0242] Table 1: R 1 , R 2 Definition of substituents of X, Y and D:

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250]

[0251]

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271] Table A-2 provides 672 compounds A-2.001 to A-2.672 of formula (I), wherein G is -H, W is (E)-CH=CH-, and R1 , R 2 , X, Y, and D are as defined in Table 1 above for compound numbers 1.001 to 1.672, respectively.

[0272] Table A-3 provides 672 compounds A-3.001 to A-3.672 having formula (I), wherein G is -(C=O)iPr, W is -CH2-CH2-, and R 1 , R 2 , X, Y, and D are as defined in Table 1 above for compound numbers 1.001 to 1.672, respectively.

[0273] Table A-4 provides 672 compounds A-4.001 to A-4.672 of formula (I), wherein G is -(C=O)iPr, W is (E)-CH=CH-, and R 1 , R 2 , X, Y, and D are as defined in Table 1 above for compound numbers 1.001 to 1.672, respectively.

[0274] Table B-1 provides 744 compounds B-1.001 to B-1.744 having formula (I), wherein G is -H, W is -CH2-CH2-, X is 6-cyclopropyl, and R 1 , R 2 , Y, and D are defined as in Table 2 below for compound numbers 2.001 to 2.744, respectively.

[0275] Table 2: R 1 , R 2 Definition of substituents of Y and D:

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285]

[0286]

[0287]

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297]

[0298]

[0299]

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306] Table B-2 provides 744 compounds B-2.001 to B-2.744 of formula (I), wherein G is -H, W is (E)-CH=CH-, X is 6-cyclopropyl, and R 1 , R 2 , Y, and D are as defined in Table 2 above for compound numbers 2.001 to 2.744, respectively.

[0307] Table B-3 provides 744 compounds B-3.001 to B-3.744 of formula (I), wherein G is -(C=O)iPr, W is -CH2-CH2-, X is 6-cyclopropyl, and R 1 , R 2 , Y, and D are as defined in Table 2 above for compound numbers 2.001 to 2.744, respectively.

[0308] Table B-4 provides 744 compounds B-4.001 to B-4.744 of formula (I), wherein G is -(C=O)iPr, W is (E)-CH=CH-, X is 6-cyclopropyl, and R 1 , R 2 , Y, and D are as defined in Table 2 above for compound numbers 2.001 to 2.744, respectively.

[0309] Table C-1 provides 744 compounds C-1.001 to C-1.744 having formula (I), wherein G is -H, W is -CH2-CH2-, Y is 3-cyclopropyl, and R 1 , R 2 , X and D are as defined in Table 3 below for compound numbers 3.001 to 3.744, respectively.

[0310] Table 3: R 1 , R 2 Definition of Substituents of X and D

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320]

[0321]

[0322]

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338]

[0339]

[0340]

[0341] Table C-2 provides 744 compounds C-2.001 to C-2.744 of formula (I), wherein G is -H, W is (E)-CH=CH-, Y is 3-cyclopropyl, and R 1 , R 2 , X, Y and D are as defined above in Table 3 for compound numbers 3.001 to 3.744, respectively.

[0342] Table C-3 provides 744 compounds C-3.001 to C-3.744 of formula (I), wherein G is -(C=O)iPr, W is -CH2-CH2-, Y is 3-cyclopropyl, and R 1 , R 2, X and D are as defined above in Table 3 for compound numbers 3.001 to 3.744, respectively.

[0343] Table C-4 provides 744 compounds C-4.001 to C-4.744 of formula (I), wherein G is -(C=O)iPr, W is (E)-CH=CH-, Y is 3-cyclopropyl, and R 1 , R 2 , X and D are as defined above in Table 3 for compound numbers 3.001 to 3.744, respectively.

[0344] The compounds of the present invention can be prepared according to the following schemes, wherein the substituent R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , W, D, Dp, G, X, Y and m have the definitions set out above unless expressly stated otherwise.

[0345] Certain compounds (I-ii) of the present invention can be prepared from compound (2) as shown in Reaction Scheme 1. Compound (I-ii) is a compound having formula (I) wherein W is -CH2-CH2-.

[0346] Reaction Scheme 1

[0347]

[0348] Compound (I-ii) can be prepared by catalytic hydrogenation of compound (2) with hydrogen in a suitable solvent [such as tetrahydrofuran, methanol, ethanol, acetic acid or ethyl acetate] in the presence of a suitable catalyst [such as Pd / C, Pd / CaCO3, Rh / Al2CO3 or sponge nickel] at a temperature between -10°C and 100°C.

[0349] Alternatively, compound (I-ii) can also be prepared by catalytic transfer hydrogenation of compound (2) by treatment with a suitable hydrogen source in a suitable solvent in the presence of a suitable catalyst at a temperature between -10°C and 100°C. Examples of suitable systems are tetrahydroxydiboron in dichloromethane / water or dichloromethane / methanol mixtures in the presence of Pd / C, Pd(OAc)2 or Pd(OH)2 / C (J. Am. Chem. Soc., 2016, 138, 6107-6110) or diethyl 1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate in ethanol in the presence of Pd / C (Tetrahedron Letters, 2009, 50, 1026).

[0350] As shown in Reaction Scheme 2, compound (2) can be prepared from compound (3) and compound (4) according to the Suzuki Protocol or Heck Protocol described below. When the Suzuki Protocol is used, compound (4) is an organic boron compound such as boronic acid, boric acid ester or potassium trifluoroborate. When the Heck Protocol is used, compound (4) is styrene.

[0351] Alternatively, compound (I-ii) can also be prepared by reduction with an imide generated in situ from a suitable precursor in a suitable solvent at a temperature between -10°C and 200°C. Examples of suitable reagents for generating imide include substituted arylsulfonyl hydrazides, such as 2,4,6-triisopropylbenzenesulfonyl hydrazides, optionally in the presence of a suitable base. Examples of suitable bases include triethylamine, diisopropylethylamine, potassium carbonate and sodium carbonate. Suitable solvents include tetrahydrofuran, 1,4-dioxane, ethyl acetate, acetonitrile and dimethylformamide.

[0352] Reaction Scheme 2

[0353]

[0354] Suzuki Protocol

[0355] Compound (2) can be prepared by treating compound (3) with compound (4) in the presence of a suitable base and a suitable catalyst in a suitable solvent at a temperature between 10°C and 150°C. Examples of suitable bases include potassium carbonate, potassium phosphate, sodium carbonate, sodium bicarbonate and potassium fluoride. Examples of suitable catalysts include 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane complex [PdCl2(dppf).DCM], tetrakis(triphenylphosphine)palladium(0)[Pd(PPh3)4], and a catalytic system formed in situ by a mixture of palladium(II) acetate and triphenylphosphine. Examples of suitable solvents include water, 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene. Many compounds (4) are commercially available [e.g., trans-2-(4-biphenyl)vinylboronic acid] or can be prepared by known methods. An example of a compound (3) having particular utility in the Suzuki protocol is the isobutyryl ester (3-i) wherein G is isobutyryl.

[0356] The skilled artisan will appreciate that the conditions of the Suzuki protocol readily cleave the ester group, such that Reaction Scheme 2 may also describe a reaction in which the starting material (3) contains an ester moiety [such that G is acyl], but the product (2) does not [such that G is hydrogen].

[0357] Heck Protocol

[0358] Compound (2) can be prepared by treating compound (3) with compound (4) in the presence of a suitable base and a suitable catalyst at a temperature between 10°C and 150°C. Additional solvents may optionally be included. Examples of suitable bases include triethylamine, morpholine, N-methylmorpholine, diisopropylethylamine and pyridine. Examples of suitable catalysts include tetrakis(triphenylphosphine)palladium(0)[Pd(PPh3)4], a catalytic system formed in situ from a mixture of palladium(II) acetate and triphenylphosphine, a catalytic system formed in situ from a mixture of tris(dibenzylideneacetone)dipalladium(0) and tri-tert-butylphosphonium tetrafluoroborate, and a catalytic system formed in situ from a cyclopalladium complex precatalyst such as chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II). Examples of optional additional solvents include 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene. Many compounds (4) are commercially available [such as 4-cyanostyrene] or can be prepared by known methods. An example of a compound (3) having particular utility in the Heck protocol is the isobutyryl ester (3-i), wherein G is isobutyryl.

[0359] As shown in Reaction Scheme 3, compound (3-i) can be produced from compound (5).

[0360] Reaction Scheme 3

[0361]

[0362] Compound (3-i) can be prepared by treating compound (5) with isobutyryl chloride in a suitable solvent [such as dichloromethane, acetonitrile or toluene] in the presence of a suitable base [such as triethylamine, diisopropylethylamine or pyridine] at a temperature between -10°C and 60°C. A catalyst [such as 4-(dimethylamino)pyridine] may optionally be included.

[0363] As shown in Reaction Scheme 4, compound (5) can be prepared from compound (6) by heating compound (6) with a base (such as 1,8-diazabicyclo[5.4.0]undec-7-ene, sodium hexamethyldisilazane or lithium hexamethyldisilazane) in a solvent (such as acetonitrile, N,N-dimethylformamide or toluene) at a temperature between 50° C. and 200° C. Conventional heating or microwave heating can be used.

[0364] Reaction Scheme 4

[0365]

[0366] As shown in Reaction Scheme 5, compound (6) can be prepared from phenylacetic acid (7).

[0367] Reaction Scheme 5

[0368]

[0369] With respect to Reaction Scheme 5, an example of a hydrazine (8) is methylhydrazine, and an example of a ketoester (10) is ethyl pyruvate. An example of a hydrazone (9) is ethyl (2E / Z)-2-(methylhydrazine)propionate, prepared according to the method described in PCT patent application WO 2016 / 008816. An example of a phenylacetic acid (7) is (2-bromo-6-fluoro-phenyl)acetic acid, which can be synthesized according to Reaction Scheme 10. Another example of a phenylacetic acid (7) is (2-bromo-3-chloro-6-fluoro-phenyl)acetic acid, which can be synthesized according to Reaction Scheme 11.

[0370] Certain compounds (I-iii) of the present invention can be prepared from compound (11) (as shown in Reaction Scheme 6) or compound (I-iv) (as shown in Reaction Scheme 12). Compound (I-iii) is a compound having formula (I) wherein W is -CH2-CH2- and G is hydrogen.

[0371] Reaction Scheme 6

[0372]

[0373] Compound (I-iii) can be prepared by heating compound (11) and a base (such as 1,8-diazabicyclo[5.4.0]undec-7-ene, sodium hexamethyldisilazane or lithium hexamethyldisilazane) in a solvent (such as acetonitrile, N,N-dimethylformamide or toluene) at a temperature between 50° C. and 200° C. Conventional heating or microwave heating can be used.

[0374] As shown in the following Reaction Scheme 7, compound (11) can be prepared from compound (12).

[0375] Reaction Scheme 7

[0376]

[0377] Compound (12) can be prepared from compound (13) as shown in Reaction Scheme 8. Many compounds (13) are commercially available [such as methyl 2-phenylacetate and methyl 2-(2-fluorophenyl)acetate].

[0378] Regarding Reaction Scheme 8, phosphorane (15) can be prepared according to Reaction Scheme 9.

[0379] Reaction Scheme 8

[0380]

[0381] Reaction Scheme 9

[0382]

[0383] With respect to Reaction Scheme 9, examples of suitable bases are sodium hydride, sodium hexamethyldisilazane and potassium tert-butoxide. Compound (16) is an electrophile in which LG is a leaving group [such as chloride, bromide, iodide, tosylate or mesylate]. Many compounds (16) are commercially available [such as 4-chlorobenzyl bromide or 2-chloro-5-chloromethylthiazole].

[0384] Reaction Scheme 10

[0385]

[0386] Referring to Reaction Scheme 10, (2-bromo-6-fluoro-phenyl)acetic acid ethyl ester can be prepared as described in Lundgren et al. JACS 2016, 138, 13826-13829.

[0387] Reaction Scheme 11

[0388]

[0389] With respect to Reaction Scheme 11, 2-bromo-1-chloro-4-fluoro-benzene is commercially available.

[0390] Reaction Scheme 12

[0391]

[0392] Compound (I-iii) can be prepared by treating compound (I-iv) with a metal hydroxide [such as sodium hydroxide, lithium hydroxide or potassium hydroxide] in a mixture of water and a suitable solvent [such as methanol, ethanol or tetrahydrofuran]; or treating compound (I-iv) with a metal carbonate [such as sodium carbonate or potassium carbonate] in an alcohol solvent [such as methanol or ethanol] at a temperature between 0°C and 100°C. Compound (I-iv) is a compound of formula (I) wherein W is -CH2-CH2- and G is C(O)R 3 .

[0393] As shown in Reaction Scheme 13, compound (2) can be prepared from compound (14) and compound (15) according to the Suzuki protocol or Heck protocol described below. When the Suzuki protocol is used, compound (14) is an organoboron compound such as boronic acid, boronic ester or potassium trifluoroborate and compound (15) is a halide or pseudohalide compound such as chloride, bromide, iodide or triflate. When the Heck protocol is used, compound (14) is styrene and compound (15) is a halide or pseudohalide compound such as chloride, bromide, iodide or triflate.

[0394] Reaction Scheme 13

[0395]

[0396] Suzuki Protocol

[0397] Compound (2) can be prepared by treating compound (14) with compound (15) in the presence of a suitable base and a suitable catalyst in a suitable solvent at a temperature between 10°C and 150°C. Examples of suitable bases include potassium carbonate, potassium phosphate, sodium carbonate, sodium bicarbonate and potassium fluoride. Examples of suitable catalysts include 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane complex [PdCl2(dppf).DCM], tetrakis(triphenylphosphine)palladium(0)[Pd(PPh3)4], and a catalytic system formed in situ from a mixture of palladium(II) acetate and triphenylphosphine. Examples of suitable solvents include water, 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene. Many compounds (15) are commercially available or can be prepared by known methods. An example of a compound (14) having particular utility in the Suzuki protocol is isobutyryl ester (14-i), wherein G is isobutyryl.

[0398] The skilled artisan will appreciate that the conditions of the Suzuki protocol readily cleave ester groups, such that reaction scheme 13 may also describe a reaction in which the starting material (14) contains an ester moiety [such that G is acyl], but the product (2) does not [such that G is hydrogen].

[0399] Heck Protocol

[0400] Compound (2) can be prepared by treating compound (14) with compound (15) in the presence of a suitable base and a suitable catalyst at a temperature between 10°C and 150°C. Additional solvents may optionally be included. Examples of suitable bases include triethylamine, morpholine, N-methylmorpholine, diisopropylethylamine and pyridine. Examples of suitable catalysts include tetrakis(triphenylphosphine)palladium(0)[Pd(PPh3)4], a catalytic system formed in situ from a mixture of palladium(II) acetate and triphenylphosphine, a catalytic system formed in situ from a mixture of tris(dibenzylideneacetone)dipalladium(0) and tri-tert-butylphosphonium tetrafluoroborate, and a catalytic system formed in situ from a cyclopalladium complex precatalyst such as chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II). Examples of optional additional solvents include 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene. Many compounds (15) are commercially available or can be prepared by known methods. An example of a compound (14) having particular utility in the Heck protocol is the isobutyryl ester (14-i), wherein G is isobutyryl.

[0401] As shown in Reaction Scheme 14, compound (14-ii) can be prepared from compound (3) and compound (16), wherein J is an organoboron species such as a borate ester.

[0402] Reaction Scheme 14

[0403]

[0404] Compound (14-ii) can be prepared by treating compound (3) with compound (16) in the presence of a suitable base and a suitable catalyst at a temperature between 10°C and 150°C. Additional solvents may optionally be included. Examples of suitable bases include triethylamine, morpholine, N-methylmorpholine, diisopropylethylamine and pyridine. Examples of suitable catalysts are tetrakis(triphenylphosphine)palladium(0)[Pd(PPh3)4], a catalytic system formed in situ by a mixture of palladium(II) acetate and triphenylphosphine, and a catalytic system formed in situ by a mixture of tris(dibenzylideneacetone)dipalladium(0) and tri-tert-butylphosphonium tetrafluoroborate. Examples of optional additional solvents include 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene. Many compounds (16) are commercially available, such as vinylboronic acid MIDA ester or vinylboronic acid pinacol ester, or may be prepared by known methods. An example of a compound (3) having particular utility in the Heck protocol is the isobutyryl ester (3-i), wherein G is isobutyryl.

[0405] As shown in Reaction Scheme 15, compound (14-iii) (wherein J is hydrogen) can be prepared from compound (3).

[0406] Reaction Scheme 15

[0407]

[0408] Compound (14-iii) can be prepared by treating compound (3) with tributyl(vinyl)stannane in a suitable solvent at a temperature between 10°C and 150°C, optionally in the presence of a suitable base, in the presence of a suitable catalyst. Examples of the optional base include triethylamine, morpholine, N-methylmorpholine, diisopropylethylamine and pyridine. Examples of suitable catalysts include 1,1′-bis(diphenylphosphino)-ferrocene]dichloropalladium(II)dichloromethane complex [PdCl2(dppf).DCM], tetrakis(triphenylphosphine)palladium(0)[Pd(PPh3)4], a catalytic system formed in situ from a mixture of palladium(II) acetate and triphenylphosphine, a catalytic system formed in situ from a mixture of tris(dibenzylideneacetone)dipalladium(0) and tri-tert-butylphosphonium tetrafluoroborate, and a catalytic system formed in situ from a cyclopalladium complex precatalyst such as chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II). Examples of suitable solvents include 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene.An example of a compound (3) of particular utility is the isobutyryl ester (3-i) wherein G is isobutyryl.

[0409] As shown in Reaction Scheme 16, compound (18) can be prepared from compound (3) by Sonogashira reaction.

[0410] Reaction Scheme 16

[0411]

[0412] Compound (18) can be prepared by treating compound (3) with compound (17) in the presence of a suitable base and one or more suitable catalysts at a temperature between 10°C and 150°C. Optionally, an additional solvent may be added. Examples of suitable bases include triethylamine, morpholine, N-methylmorpholine, diisopropylamine, diisopropylethylamine and pyridine. Examples of suitable catalysts include bis(triphenylphosphine)palladium(II)dichloride [Pd(PPh3)Cl2], a catalytic system formed in situ by a mixture of palladium acetate(II) and triphenylphosphine, a catalytic system formed in situ by a mixture of tri(dibenzylideneacetone)dipalladium(0) and tri-tert-butylphosphonium tetrafluoroborate, and a catalytic system formed in situ by a cyclopalladium complex precatalyst such as chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II). Optionally, a copper catalyst such as copper(I) iodide may also be added. Examples of suitable additional solvents are 1,4-dioxane, tetrahydrofuran, acetonitrile, toluene and N,N-dimethylformamide.An example of a compound (3) of particular utility is the isobutyryl ester (3-i) wherein G is isobutyryl.

[0413] The skilled artisan will appreciate that the conditions of the Sonogashira reaction tend to cleave the ester group, so that reaction scheme 16 can also describe a reaction in which the starting material (3) contains an ester moiety [such that G is acyl], but the product (18) does not [such that G is hydrogen].

[0414] As shown in Reaction Scheme 17, compound (19) can be prepared from compound (3) and compound (20) by Suzuki reaction, wherein compound (20) is a suitable organoboron species, such as boronic acid, boronic ester or potassium trifluoroborate.

[0415] Reaction Scheme 17

[0416]

[0417] Compound (19) can be prepared by treating compound (3) with compound (20) in the presence of a suitable base and a suitable catalyst in a suitable solvent at a temperature between 10° C. and 150° C. Examples of suitable bases include potassium carbonate, potassium phosphate, sodium carbonate, sodium bicarbonate and potassium fluoride. Examples of suitable catalysts include 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane complex [PdCl2(dppf).DCM], a catalytic system formed in situ from a mixture of tri(dibenzylideneacetone)dipalladium(0) and tri-tert-butylphosphonium tetrafluoroborate, a catalytic system formed in situ from a mixture of tri(dibenzylideneacetone)dipalladium(0) and tricyclohexylphosphine, a catalytic system formed in situ from a cyclopalladium complex precatalyst such as chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II), and a catalytic system formed in situ from a cyclopalladium complex precatalyst such as chloro[(tricyclohexylphosphine)-2-(2′-aminobiphenyl)]palladium(II). Examples of suitable solvents include water, 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene. Some compounds (20) are commercially available [such as 4,4,5,5-tetramethyl-2-(2-phenyl-cyclopropyl)-[1,3,2]dioxaborolane] or can be prepared by known methods (see, for example, the methods described in Org. Process Res. Dev. [Organic Process Research and Development], 2012, 16, 87-95). An example of a compound (3) having particular utility in the Suzuki reaction is a benzyl ether (3-ii), wherein G is a benzyl group.

[0418] Reaction Scheme 18

[0419]

[0420] Compound (I9-ii) can be prepared by catalytic hydrogenation of compound (19-i) with hydrogen in a suitable solvent [such as tetrahydrofuran, methanol, ethanol, acetic acid or ethyl acetate] in the presence of a suitable catalyst [such as Pd / C, Pd / CaCO3, Rh / Al2CO3 or sponge nickel] at a temperature between -10°C and 100°C.

[0421] Certain compounds (I-ii) of the present invention can be prepared from compound (21) as shown in Reaction Scheme 19. Compound (I-ii) is a compound having formula (I) wherein W is -CH2-CH2-.

[0422] Reaction Scheme 19

[0423]

[0424] Compound (I-ii) can be prepared by treating compound (21) (wherein [B] can be trialkylborane, alkylboronic acid, alkylboronic acid ester or alkyl trifluoroborate potassium salt) with compound (15) in the presence of a suitable base and a suitable catalyst in a suitable solvent at a temperature between 10°C and 150°C. Examples of suitable bases include potassium carbonate, potassium phosphate, sodium carbonate, cesium carbonate, sodium bicarbonate and potassium fluoride. Examples of suitable catalysts include 1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) dichloromethane complex [PdCl2(dppf).DCM], [1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)dichloropalladium(II) [Pd-PEPPSI TM -IPent], a catalytic system formed in situ by a cyclopalladium complex precatalyst such as chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)[RuPhos-Pd-G2], [dicyclohexyl[2′,4′,6′-tri(1-methylethyl)[1,1′-biphenyl]-2-yl]phosphine](methanesulfonyl-κO)[2′-(methylamino-κN)[1,1′-biphenyl]-2-yl-κC]palladium[XPhos-Pd-G4], and [(4-(N,N-dimethylamino)phenyl)di-tert-butylphosphine](methanesulfonyl-κO)[2′-(methylamino-κN)[1,1′-biphenyl]-2-yl-κC]palladium[APhos-Pd-G4]. Examples of suitable solvents include water, 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene. Many compounds (15) are commercially available or can be prepared by known methods. An example of a compound (21) having particular utility in the Suzuki protocol is an isobutyryl ester (21-i), wherein G is isobutyryl.

[0425] The skilled artisan will appreciate that the conditions of the Suzuki protocol readily cleave ester groups, such that reaction scheme 19 may also describe a reaction in which the starting material (21) contains an ester moiety [such that G is acyl], but the product (I-ii) does not [such that G is hydrogen].

[0426] Reaction Scheme 20

[0427]

[0428] Compound (21) can be prepared by hydroboration of olefin (14-iii) using a suitable hydroboration agent (22) in a suitable solvent, optionally with the addition of a suitable catalyst, at a temperature between 0°C and 100°C. Examples of hydroboration agents include borane, dichloroborane, dibromoborane, 4,4,5,5-tetramethyl-1,3,2-dioxaborolane [pinacol borane], 1,3,2-benzodioxaborolane [catechol borane] or 9-borylbicyclo[3.3.1]nonane [9-BBN]. Examples of suitable solvents include tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, 2-methoxy-2-methyl-propane [MTBE) and diethyl ether. Examples of suitable catalysts include catalytic systems formed in situ from bis(1,5-cyclooctadiene)diiridium(I)dichloride [[Ir(COD)Cl]2], and 4-diphenylphosphanebutyl(diphenyl)phosphane [DPPB] [J.Am.Chem.Soc., 2004, 126, 9200-9201].

[0429] When [B] is an alkyl borate, this can be converted to the corresponding boronic acid by treatment with methylboronic acid [MeB(OH)2] and trifluoroacetic acid in a suitable solvent such as dichloromethane [DCM] at a temperature between 0°C and 40°C [Org. Lett. [Organic Express], 2019, 21, 3048-3052]. When [B] is an alkyl boronic acid or ester, this can be converted to the corresponding alkyl trifluoroborate potassium salt by treatment with potassium bifluoride in a suitable solvent such as methanol or acetone at a temperature between 0°C and 40°C.

[0430] Reaction Scheme 21

[0431]

[0432] Compound (I-iii) (wherein Y is cyclopropyl) can be prepared by treating compound (Iv) with compound (23) (wherein [B] can be trialkylborane, alkylboronic acid, alkylboronic acid ester or alkyl trifluoroborate potassium salt) in the presence of a suitable base and a suitable catalyst in a suitable solvent at a temperature between 10°C and 150°C. Compound (Iv) is a compound of formula (I) wherein C is -CH2-CH2-, G is C(o)R 3 and Y is -Cl. Examples of suitable bases include potassium carbonate, potassium phosphate, sodium carbonate, cesium carbonate, sodium bicarbonate and potassium fluoride. Examples of suitable catalysts include 1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) dichloromethane complex [PdCl2(dppf).DCM], [1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)dichloropalladium(II) [Pd-PEPPSITM -IPent], a catalytic system formed in situ by a cyclopalladium complex precatalyst such as chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)[RuPhos-Pd-G2], [dicyclohexyl[2′,4′,6′-tri(1-methylethyl)[1,1′-biphenyl]-2-yl]phosphine](methanesulfonyl-κO)[2′-(methylamino-κN)[1,1′-biphenyl]-2-yl-κC]palladium[XPhos-Pd-G4], and [(4-(N,N-dimethylamino)phenyl)di-tert-butylphosphine](methanesulfonyl-κO)[2′-(methylamino-κN)[1,1′-biphenyl]-2-yl-κC]palladium[APhos-Pd-G4]. Examples of suitable solvents include water, 1,4-dioxane, tetrahydrofuran, acetonitrile and toluene.An example of a compound (Iv) having particular utility in the Suzuki protocol is the isobutyryl ester (Iv) wherein G is isobutyryl.

[0433] The skilled artisan will appreciate that the conditions of the Suzuki protocol readily cleave ester groups, such that Reaction Scheme 21 may describe a reaction in which the starting material (Iv) contains an ester moiety [such that G is acyl], but the product (I-iii) does not [such that G is hydrogen].

[0434] The compounds of formula (I) according to the present invention can be used as herbicides themselves, but they are usually formulated into herbicidal compositions using formulation adjuvants such as carriers, solvents and surfactants (SFA). Therefore, the present invention further provides a herbicidal composition comprising a herbicidal compound according to any one of the preceding claims and an agriculturally acceptable formulation adjuvant. The composition can be in the form of a concentrate, which is diluted before use, although ready-to-use compositions can also be made. Final dilution is usually carried out with water, but for example liquid fertilizers, micronutrients, biological organisms, oils or solvents can be used in place of water or in addition to water.

[0435] The herbicidal compositions generally comprise from 0.1 to 99% by weight, in particular from 0.1 to 95% by weight, of a compound of formula I and from 1 to 99.9% by weight of formulation adjuvants, which preferably include from 0 to 25% by weight of surface-active substances.

[0436] The compositions may be selected from a variety of formulation types, many of which are known from the Manual on Development and Use of FAO Specifications for Plant Protection Products, 5th edition, 1999. These include dustable powders (DP), soluble powders (SP), water-soluble granules (SG), water-dispersible granules (WG), wettable powders (WP), granules (GR) (slow-release or fast-release), soluble concentrates (SL), oil-miscible liquids (OL), ultra-low volume liquids (UL), emulsifiable concentrates (EC), dispersible concentrates (DC), emulsions (both oil-in-water (EW) and water-in-oil (EO)), microemulsions (ME), suspension concentrates (SC), aerosols, capsule suspensions (CS) and seed treatment formulations. The formulation type chosen in any case will depend on the particular purpose envisaged and the physical, chemical and biological properties of the compound of formula (I).

[0437] Dustable powders (DP) can be prepared by mixing a compound of formula (I) with one or more solid diluents (e.g., natural clays, kaolin, pyrophyllite, bentonite, alumina, montmorillonite, kieselguhr, chalk, diatomaceous earths, calcium phosphate, calcium and magnesium carbonates, sulphur, lime, flour, talc and other organic and inorganic solid carriers) and mechanically grinding the mixture into a fine powder.

[0438] Soluble powders (SP) can be prepared by mixing a compound of formula (I) with one or more water-soluble inorganic salts (such as sodium bicarbonate, sodium carbonate or magnesium sulfate) or one or more water-soluble organic solids (such as polysaccharides) and optionally one or more wetting agents, one or more dispersants or a mixture of said agents to improve water dispersibility / water solubility. The mixture is then ground into a fine powder. Similar compositions can also be granulated to form water-soluble granules (SG).

[0439] Wettable powders (WP) can be prepared by mixing a compound of formula (I) with one or more solid diluents or carriers, one or more wetting agents and preferably, one or more dispersants, and optionally, one or more suspending agents to facilitate dispersion in a liquid. The mixture is then ground into a fine powder. Similar compositions can also be granulated to form water dispersible granules (WG).

[0440] Granules (GR) may be formed by granulating a mixture of a compound of formula (I) and one or more powdered solid diluents or carriers, or by absorbing the compound of formula (I) (or a solution thereof in a suitable agent) into a porous granular material such as pumice, attapulgite clay, Fuller's earth, kieselguhr, diatomaceous earths or corn cob meal, or from preformed blank particles by adsorbing the compound of formula (I) (or a solution thereof in a suitable agent) onto a hard core material such as sand, silicates, mineral carbonates, sulfates or phosphates and, if necessary, drying. Agents commonly used to aid absorption or adsorption include solvents such as aliphatic and aromatic petroleum solvents, alcohols, ethers, ketones and esters and adhesives such as polyvinyl acetate, polyvinyl alcohol, dextrins, sugars and vegetable oils. One or more other additives may also be included in the granules (e.g., emulsifiers, wetting agents or dispersants).

[0441] Dispersible concentrates (DC) can be prepared by dissolving a compound of formula (I) in water or an organic solvent such as a ketone, alcohol or glycol ether. These solutions may contain a surfactant (for example to improve water dilution or to prevent crystallization in a spray tank).

[0442] Emulsifiable concentrates (EC) or oil-in-water emulsions (EW) can be prepared by dissolving a compound of formula (I) in an organic solvent (optionally containing one or more wetting agents, one or more emulsifiers or a mixture of said agents). Suitable organic solvents for use in ECs include aromatic hydrocarbons (such as alkylbenzenes or alkylnaphthalenes, for example SOLVESSO 100, SOLVESSO 150 and SOLVESSO 200; SOLVESSO is a registered trademark), ketones (such as cyclohexanone or methylcyclohexanone) and alcohols (such as benzyl alcohol, furfuryl alcohol or butanol), N-alkylpyrrolidones (such as N-methylpyrrolidone or N-octylpyrrolidone), dimethylamides of fatty acids (such as C8-C 10 EC products can spontaneously emulsify when added to water, producing an emulsion with sufficient stability to allow spray application by appropriate equipment.

[0443] The preparation of EWs involves obtaining a compound of formula (I) as a liquid (if it is not liquid at room temperature, it can be melted at a reasonable temperature, typically below 70° C.) or in solution (by dissolving it in a suitable solvent), and then emulsifying the resulting liquid or solution into water containing one or more SFAs under high shear to produce an emulsion. Suitable solvents for use in EWs include vegetable oils, chlorinated hydrocarbons (such as chlorobenzene), aromatic solvents (such as alkylbenzenes or alkylnaphthalenes) and other suitable organic solvents having low solubility in water.

[0444] Microemulsion (ME) can be prepared by mixing water with a blend of one or more solvents and one or more SFAs to spontaneously produce a thermodynamically stable isotropic liquid formulation. The compound with formula (I) is initially present in water or in a solvent / SFA blend. The suitable solvent used in ME includes those used in EC or EW described herein before. ME can be an oil-in-water system or an oil-in-water system (which system exists can be measured by conductivity testing) and can be applicable to mixing water-soluble and oil-soluble pesticides in the same formulation. ME is applicable to dilution in water, remains as a microemulsion or forms a conventional oil-in-water emulsion.

[0445] Suspension concentrates (SC) may include aqueous or non-aqueous suspensions of finely dispersed insoluble solid particles of a compound of formula (I). SC may be prepared by ball milling or bead milling a solid compound of formula (I) with one or more dispersants in a suitable medium to produce a fine particle suspension of the compound. One or more wetting agents may be included in the composition, and a suspending agent may be included to reduce the sedimentation rate of the particles. Alternatively, a compound of formula (I) may be dry-milled and added to water containing the reagents described hereinabove to produce a desired end product.

[0446] Aerosol formulations include a compound of formula (I) and a suitable propellant (e.g., n-butane). The compound of formula (I) may also be dissolved or dispersed in a suitable medium (e.g., water or a water-miscible liquid such as n-propanol) to provide a composition for use in a non-pressurized, hand-operated spray pump.

[0447] Capsule suspensions (CS) can be prepared in a similar manner to the preparation of EW formulations, but with an additional polymerization stage, so that an aqueous dispersion of oil droplets is obtained, each of which is wrapped by a polymer shell and contains a compound of formula (I) and optionally a carrier or diluent thereof. The polymer shell can be produced by an interfacial polycondensation reaction or by a coacervation procedure. These compositions can provide controlled release of compounds of formula (I) and they can be used for seed treatment. Compounds of formula (I) can also be formulated in a biodegradable polymer matrix to provide slow, controlled release of the compound.

[0448] The composition may contain one or more additives to improve the biological performance of the composition, for example by improving wettability, retention or distribution on a surface; rain resistance on a treated surface; or absorption or flow of a compound of formula (I). Such additives include surfactants (SFAs), oil-based spray additives, such as certain mineral oils or natural vegetable oils (such as soybean and rapeseed oils), and blends of these with other bioenhancement adjuvants (ingredients that assist or modify the action of a compound of formula (I)).

[0449] The wetting agents, dispersants and emulsifiers may be SFAs of the cationic, anionic, amphoteric or nonionic type.

[0450] Suitable SFAs of the cationic type include quaternary ammonium compounds (eg cetyltrimethylammonium bromide), imidazolines and amine salts.

[0451] Suitable anionic SFAs include alkali metal salts of fatty acids, salts of fatty sulfuric acid monoesters (for example sodium lauryl sulfate), salts of sulfonated aromatic compounds (for example sodium dodecylbenzenesulfonate, calcium dodecylbenzenesulfonate, butylnaphthalenesulfonate and mixtures of sodium di-isopropyl-naphthalenesulfonate and sodium tri-isopropyl-naphthalenesulfonate), ether sulfates, alcohol ether sulfates (for example sodium laureth-3-sulfate), ether carboxylates (for example sodium laureth-3-carboxylate), phosphates (products from the reaction of one or more fatty alcohols with phosphoric acid (mainly monoesters) or with phosphorus pentoxide (mainly diesters), for example the reaction of lauryl alcohol with tetraphosphoric acid; these products may additionally be ethoxylated), sulfosuccinamates, paraffin or olefin sulfonates, taurates and lignosulfonates.

[0452] Suitable SFAs of the amphoteric type include betaines, propionates and glycinates.

[0453] Suitable SFAs of the nonionic type include condensation products of alkylene oxides (e.g. ethylene oxide, propylene oxide, butylene oxide or mixtures thereof) with fatty alcohols (e.g. oleyl alcohol or cetyl alcohol) or with alkylphenols (e.g. octylphenol, nonylphenol or octylcresol); partial esters derived from long-chain fatty acids or hexitol anhydrides; condensation products of said partial esters with ethylene oxide; block polymers (containing ethylene oxide and propylene oxide); alkanolamides; monoesters (e.g. fatty acid polyethylene glycol esters); amine oxides (e.g. lauryl dimethyl amine oxide); and lecithin.

[0454] Suitable suspending agents include hydrophilic colloids (such as polysaccharides, polyvinylpyrrolidone or sodium carboxymethylcellulose) and swelling clays (such as bentonite or attapulgite).

[0455] Compositions of the present invention may further comprise at least one additional pesticide. For example, compounds according to the present invention may also be used in combination with other herbicides or plant growth regulators. In a preferred embodiment, the additional pesticide is a herbicide and / or a herbicide safener. Specific examples of such mixtures include (wherein "I" represents a compound having formula (I)): I+acetochlor; I+ acifluorfen (including acifluorfen-sodium); I+ bensulfuron; I+ ametryn; I+ amitriptyline; I+ aminopyralid; I+ cypermethrin; I+ atrazine; I+ beflubutamid-M; I+ benquitrione; I+ benzylsulfuron-methyl (including benzylsulfuron-methyl); I+ thiamethoxam; I+ bicyclopyrone; I+ bialaphos; I+ bispyribac-sodium; I+ bixlozone; I+ herbicide; I+ bromoxynil; I+ butachlor; I+ fluazifop-butyl; I+ pyraclostrobin (including pyraclostrobin-butyl); ester-ethyl); chlorsulfuron (including chlorsulfuron-methyl); I+ chlorimuron-methyl (including chlorimuron-ethyl); I+ chlorotoluron; I+ chlorsulfuron; I+ cyproconazole; I+ clacyfos; I+ clethodim; I+ clodinafop-butyl (including clodinafop-propyl); I+ clomazone; I+ clopyralid; I+ cyclopyranil; I+ cyclopyrimorate; I+ cyprosulfuron-methyl; I+ cyhalofop-butyl (including cyhalofop-butyl-butyl); I+ 2,4-D (including its choline salt and 2-ethylhexyl ester); I+ 2,4-DB; I+ betaine; I + dicamba (including its aluminum; aminopropyl; bis-aminopropyl methyl; choline; dichloropropane; diglycolamine; dimethylamine; dimethylammonium; potassium and sodium salts); I+ bisclorac; I+ fluazifop; I+ flufenac; I+ fluazifop-butyl; I+ dimethoate; I+ dimethoate; I+ diquat dibromide; I+ diuron; I+ epyrifenacil; I+ fluazifop-butyl; I+ ethoxyfuroxazole; I+ oxadiazine (including oxadiazine-ethyl); I+ fenoxasulfone; I+ fenoxasulfone; I+ fenquinotrione; I+ tetrazolylpyr; I+ fluazifop-butyl; I+ bisclorac; I+ chlorpyrifos (including chlorpyrifos-benzyl); I+ fluazifop-butyl (including fluazifop-butyl-butyl); I+ fluoxathiacet (including fluoxathiacet-sodium); I+ flufenacet; I+ flufenamid; I+ fluazifop-butyl; I+ flufenacet; I+ fluazifop-methyl; I+ fluroxypyr; I+ fluroxypyr-methyl (including fluroxypyr-meptyl); I+ fluroxypyr-butyl; I+ foramsulfuron; I+ glufosinate (including its ammonium salt); I+ glyphosate (including its hydrazine; isopropyl ammonium and potassium salt); I+ halauxifen (including halauxifen-methyl);I+ haloxyfop-butyl (including haloxyfop-methyl); I+ cyclazinone; I+ hydantocidin; I+ methoxyimidazopyr; I+ methylimidazopyr; I+ imazapyr; I+ imazapyr; I+ indaziflam; I+ iodosulfuron (including iodosulfuron-methyl-sodium); I+ iofensulfuron (including I+ iofensulfuron-sodium); I+ iobenzonitrile; I+ isoproturon; I+ isoxathiapiprom; I+ lancotrione; I+ MCPA; I+ MCPB; I+ mecoprop-P; I+ methyldisulfuron (including I+ methyldisulfuron-methyl); I+ mesotrione; I+ Metamitron; I+metachlor; I+methiozolin; I+isopropyl metolachlor; I+sulfuron; I+metamisulfuron; I+naprosulfuron; I+nicosulfuron; I+ norfax; I+oxadiazine; I+epoxsulfuron; I+oxyfluorfen; I+paraquat dichloride; I+pentadimethoate; I+pentasulfuron; I+bendiamide; I+piperidin; I+piperazine; I+piperidin; I+piperidin; I+pretilachlor; I+primisulfuron-methyl; I+promethazine; I+piperidin; I+fenazolin; I+propyrisulfuron; I+propyrisulfuron, I+propyrisulfuron; I+bencarb; I+prosulfuron; I+bipyramide; I+pyrasulfuron; I+pyrasulfuron-ethyl; I+sulfuron Pyrazole; I+pyridachlor; I+pyrimisulfan, I+pyroxasulfone; I+pyrosulfuron; I+quinacridone; I+quinclorac; I+quinclorac; I+quizalofop-ethyl (including quizalofop-P-tefuryl); I+sulfonesulfuron; I+pyrimidoxime; I+sethoxydim; I+simazine; I+S-isopropylmethoate; I+sulfentrazone; I+sulfentrazone; I+sulfuron; I+sulfuron; I+terbuthiazine; I+terbuthiazine; I+tetflupyrolimet; I+thiencarbazone; I+thiencarbazone Fensulfuron-methyl; I+ tiafenacil; I+ tolpyralate; I+ benpyrazone; I+ triafamone; I+ wild wheat ballast; I+ ether bensulfuron-methyl; I+ bensulfuron-methyl (including bensulfuron-methyl); I+ triclopyr; I+ trifloxysulfuron (including trifloxysulfuron-sodium); I+ trifludimoxazin; I+ trifluralin; I+ flufenacil; I+ 3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydropyrimidin-1(2H)-yl)phenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid ethyl ester;I+4-hydroxy-1-methoxy-5-methyl-3-[4-(trifluoromethyl)-2-pyridinyl]imidazolidin-2-one; I+4-hydroxy-1,5-dimethyl-3-[4-(trifluoromethyl)-2-pyridinyl]imidazolidin-2-one; I+5-ethoxy-4-hydroxy-1-methyl-3-[4-(trifluoromethyl)-2-pyridinyl]imidazolidin-2-one; I+4-hydroxy-1-methyl-3-[4-(trifluoromethyl)-2-pyridinyl]imidazolidin-2-one; I+4-hydroxy-1,5-dimethyl-3-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]imidazolidin-2-one; I+(4R)1-(5-tert-butylisoxazol-3-yl)-4 -ethoxy-5-hydroxy-3-methyl-imidazolidin-2-one; I+3-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]bicyclo[3.2.1]octane-2,4-dione; I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-5-methyl-cyclohexane-1,3-dione; I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]cyclohexane-1,3-dione; I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-5,5-dimethyl-cyclohexane-1, 3-dione; I+6-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-2,2,4,4-tetramethyl-cyclohexane-1,3,5-trione; I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-5-ethyl-cyclohexane-1,3-dione; I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-4,4,6,6-tetramethyl-cyclohexane-1,3-dione; I+2-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]-5-methyl-cyclohexane-1, 3-dione; I+3-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]bicyclo[3.2.1]octane-2,4-dione; I+2-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]-5,5-dimethyl-cyclohexane-1,3-dione; I+6-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]-2,2,4,4-tetramethyl-cyclohexane-1,3,5-trione; I+2-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]cyclohexane-1,3-dione;I + 4-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-2,2,6,6-tetramethyl-tetrahydropyran-3,5-dione; I + 4-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]-2,2,6,6-tetramethyl-tetrahydropyran-3,5-dione; I + 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl)pyridine-2-carboxylic acid (including its agrochemically acceptable esters, for example, 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl)pyridine-2-carboxylic acid 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl)pyridine-2-carboxylic acid cyanomethyl ester); 1+3-ethylsulfanyl-N-(1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide; 1+3-(isopropylsulfanylmethyl)-N- (5-methyl-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide; I+3-(isopropylsulfonylmethyl)-N-(5-methyl-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide; I+3-(ethylsulfonylmethyl)-N-(5-methyl-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine- 8-formamide; 1+2-[[3-[[3-chloro-5-fluoro-6-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]-2-pyridinyl]oxy]ethyl acetate; 1+6-chloro-4-(2,7-dimethyl-1-naphthyl)-5-hydroxy-2-methyl-pyridazin-3-one; 1+1-[2-chloro-6-(5-chloropyrimidin-2-yl)oxy-phenyl]-4,4,4-trifluoro-butan-1-one and 1+5-[2-chloro-6-(5-chloropyrimidin-2-yl)oxy-phenyl]-3-(difluoromethyl)isoxazole. ;

[0456] Mixtures of compounds of formula (I) may also be in the form of esters or salts, as mentioned, for example, in The Pesticide Manual, Fourteenth Edition, British Crop Protection Council, 2006.

[0457] The compounds of formula (I) can also be used in a mixture with other agrochemicals such as fungicides, nematicides or insecticides, examples of which are given in the Pesticide Handbook.

[0458] The mixing ratio of the compound of formula (I) to the mixing partner is preferably from 1:100 to 1000:1.

[0459] These mixtures can advantageously be used in the abovementioned formulations ("active ingredient" in this case relates to the corresponding mixture of the compound of formula (I) with the mixing partner).

[0460] The compounds of formula (I) of the present invention may also be combined with herbicide safeners. Preferred combinations (wherein "I" represents a compound of formula (I)) include:

[0461] I+ cloquintocet, I+ cloquintocet-mexyl (including cloquintocet-mexyl), I+ cyclopropylsulfonamide, I+ dichloropropyleneamine, I+ oxadiazole (including oxadiazole-ethyl), I+ chlorpyrifos, I+ fluazifop, I+ oxadiazole, I+ isoxadiazole (including isoxadiazole-ethyl), I+ pyrazole oxalate (including pyrazole oxalate-diethyl), I+ metcamifen and I+ oxadiazole.

[0462] Particularly preferred are mixtures of a compound of formula (I) with cyproconazole, isoxadifen (including isoxadifen-ethyl), cloquintocet-mexyl (including cloquintocet-mexyl) and / or N-(2-methoxybenzoyl)-4-[(methyl-aminocarbonyl)amino]benzenesulfonamide.

[0463] The safener of the compound of formula (I) may also be in the form of an ester or salt, for example as mentioned in the Handbook of Pesticides, 14th edition (BCPC), 2006. References to clofoscar-mexyl also apply to lithium, sodium, potassium, calcium, magnesium, aluminium, iron, ammonium, quaternary ammonium, sulfonium or phosphonium salts thereof (as disclosed in WO 02 / 34048), and references to fenthiocarb ethyl also apply to fenthiocarb and the like.

[0464] Preferably, the mixing ratio of compound of formula (I) to safener is from 100:1 to 1:10, in particular from 20:1 to 1:1.

[0465] The compounds of formula (I) can also be used in a mixture with other agrochemicals such as fungicides, nematicides or insecticides, examples of which are given in the Pesticide Handbook.

[0466] The mixing ratio of the compound of formula (I) to the mixing partner is preferably from 1:100 to 1000:1.

[0467] These mixtures can advantageously be used in the formulations mentioned above ("active ingredient" in this case relates to the corresponding mixture of the compound of formula I with the mixing partner).

[0468] The present invention still further provides a method of selectively controlling weeds in a locus comprising crop plants and weeds, wherein the method comprises applying to the locus a weed-controlling amount of a composition according to the invention. 'Control' means killing, reducing or delaying growth or preventing or reducing germination. Typically the plants to be controlled are unwanted plants (weeds). 'Locus' means an area where plants are growing or will grow.

[0469] The application rate of the compound of formula (I) can vary within a wide range and depends on the nature of the soil, the method of application (pre-emergence or post-emergence; seed dressing; application to seed furrows; no-till application, etc.), crop plants, one or more weeds to be controlled, the prevailing climatic conditions, and other factors governed by the method of application, the time of application, and the target crop. The compound of formula I according to the present invention is usually applied at a rate of from 10 g / ha to 2000 g / ha, especially from 50 g / ha to 1000 g / ha.

[0470] Application is usually carried out by spraying the composition, typically by means of a tractor-mounted sprayer for large areas, but other methods such as dusting (for powders), dripping or drenching may also be used.

[0471] Useful plants in which the compositions according to the invention can be used include crops such as cereals, for example barley and wheat, cotton, oilseed rape, sunflower, corn, rice, soybeans, sugar beet, sugar cane and turf.

[0472] Crop plants may also include trees, such as fruit trees, palm trees, coconut trees or other nuts. Also included are vines (such as grapes), shrub fruit trees, fruit plants and vegetables.

[0473] Crops are to be understood as also including those crops which have been rendered tolerant to herbicides or classes of herbicides (e.g. ALS-inhibitors, GS-inhibitors, EPSPS-inhibitors, PPO-inhibitors, ACCase-inhibitors and HPPD-inhibitors) by conventional methods of breeding or by genetic engineering. Examples of crops which have been rendered tolerant to imidazolinones (e.g. imazamox) by conventional methods of breeding are Summer rapeseed (canola). Examples of crops rendered tolerant to herbicides by genetic engineering methods include, for example, glyphosate- and glufosinate-resistant corn varieties that are and It is commercially available under the trade name TRANSPORT®. In particularly preferred aspects, the crop plants have been engineered to overexpress homogentisate solanesyltransferase as taught in, for example, WO 2010 / 029311.

[0474] Crops are also to be understood as those crops which have been rendered resistant to harmful insects by genetic engineering methods, such as Bt corn (resistant to the European corn borer), Bt cotton (resistant to the boll weevil) and also Bt potato (resistant to the Colorado beetle). Examples of Bt corn are Bt 176 corn hybrid (Syngenta Seeds). Bt toxins are proteins naturally produced by the soil bacterium Bacillus thuringiensis. Examples of toxins or transgenic plants capable of synthesizing such toxins are described in EP-A-451 878, EP-A-374 753, WO 93 / 07278, WO 95 / 34656, WO 03 / 052073 and EP-A-427 529. Examples of transgenic plants comprising one or more genes encoding insecticide resistance and expressing one or more toxins are (corn), (corn), (cotton), (cotton), (potato), as well as Plant crops or their seed material can both be resistant to herbicides and simultaneously resistant to insect feeding ("stacked" transgenic results). For example, seeds can be tolerant to glyphosate while having the ability to express an insecticidal Cry3 protein.

[0475] Crops are also to be understood as including those crops which have been obtained by conventional breeding methods or genetic engineering and contain so-called output traits, such as improved storage stability, higher nutritional value and improved flavour.

[0476] Other useful plants include turf grasses such as those grown commercially for lawns on golf courses, lawns, parks and roadsides, and ornamental plants such as flowers or shrubs.

[0477] These compositions can be used to control unwanted plants (collectively referred to as 'weeds'). Weeds to be controlled include monocotyledonous species such as bentgrass, alopecurus, avena, brachiaria, brome, tricholoma, sedge, crabgrass, barnyard grass, sedge, ryegrass, lycopodium, cyperus, sagittaria, scabrous grass, setaria and sorghum; and dicotyledonous species such as abutilon, amaranth, ragweed, quinoa, chrysanthemum, sedum, elaeagnus, ivy, ipomoea, nasturtium, spatholobus, sinapis, solanum, chickweed, veronica, violet and xanthium. Weeds may also include plants that may be considered crop plants but that grow outside the crop area ('escapes'), or plants that grow from seeds left over from a previously grown different crop ('volunteers'). Such volunteers or escapees may be tolerant to certain other herbicides.

[0478] Various aspects and embodiments of the invention will now be described in more detail by way of example. It will be appreciated that modifications of detail may be made without departing from the scope of the invention.

[0479] Typical abbreviations used in this article include:

[0480] br = width Dba

[0481] t Bu=tert-butyl

[0482] d = doublet

[0483] dba = dibenzylideneacetone

[0484] DCM = dichloromethane

[0485] DMSO = dimethyl sulfoxide

[0486] DPPA = diphenylphosphoryl azide

[0487] Et2O = diethyl ether

[0488] EtOAc = Ethyl acetate

[0489] h = hours

[0490] m = multiplet

[0491] Me = methyl

[0492] MeOH = methanol

[0493] Ph = Phenyl

[0494] i Pr=isopropyl

[0495] rt = room temperature

[0496] s = single peak

[0497] t = triplet

[0498] THF = Tetrahydrofuran

[0499] Preparation Example

[0500] Example 1 Preparation of 4-[3-chloro-6-fluoro-2-[2-(4-phenylphenyl)ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-1.027)

[0501]

[0502] 1.1 3-Allyl-2-bromo-1-chloro-4-fluoro-benzene

[0503] The solution of lithium diisopropylamide (2M in tetrahydrofuran, 3.6ml, 7.2mmol) is cooled to -78 ° C under nitrogen. At -78 ° C, a solution of 2-bromo-1-chloro-4-fluoro-benzene (1.0g, 4.8mmol) in tetrahydrofuran is added dropwise. The mixture is stirred at the same temperature for 45 minutes before being treated with allyl bromide (0.3ml, 5.7mmol). The reaction is continued for 2h at -78 ° C and then warmed to room temperature. The reaction is quenched with saturated NH4Cl (aqueous) and extracted with ethyl acetate. Organic matter is separated and retained, and then washed with brine. Organic matter is dried over sodium sulfate and concentrated under reduced pressure to give 3-allyl-2-bromo-1-chloro-4-fluoro-benzene (1.2g, 100%) in an oily state.

[0504]

[0505] 1 H NMR (400MHz, CDCl3)δ H :7.34-7.30(m,1H),7.01-6.96(m,1H),5.94-5.83(m,1H),5.10-5.00(m,2H),3.64-3.58(m,2H).

[0506] 1.2 2-(2-Bromo-3-chloro-6-fluoro-phenyl)acetic acid

[0507] A solution of 3-allyl-2-bromo-1-chloro-4-fluoro-benzene (15.0 g, 60.1 mmol) in dichloromethane (200 mL) was cooled to -78 ° C in a 2-necked flask. One side neck was connected to a trap containing an aqueous solution of KI. Ozone was bubbled through the solution until the starting material was completely consumed (5 hours). Air was bubbled through the solution for 10 minutes to remove excess ozone. Dimethyl sulfide (44 ml, 601 mmol) was added, and the mixture was warmed to room temperature. The reaction was continued at room temperature for 16 h.

[0508] The mixture was washed with brine (2 x 100 mL) and the organic layer was retained. The organics were dried over Na2SO4, filtered and concentrated under reduced pressure to give crude 2-(2-bromo-3-chloro-6-fluoro-phenyl)acetaldehyde (15.3 g) which was used in the next step without further purification.

[0509] Crude 2-(2-bromo-3-chloro-6-fluoro-phenyl)acetaldehyde (15.3 g, 60.8 mmol) was dissolved in a mixture of tert-butyl alcohol (92 mL) and water (46 mL) and then cooled to 0°C. 2-Methylbut-2-ene (64.5 mL, 608 mmol), sodium dihydrogen phosphate (34.6 g, 243 mmol) and sodium chlorite (16.5 g, 163 mmol) were added. The mixture was stirred for 2 h and then diluted with brine (150 mL) and 2M hydrochloric acid (150 mL). The mixture was extracted with ethyl acetate (3×100 mL). The combined organic extracts were washed with saturated aqueous sodium metabisulfite solution (100 mL), then dried over Na2SO4, filtered and concentrated under reduced pressure to provide a pale yellow solid. The crude solid was dissolved in a mixture of water (100 mL) and 2.0 M NaOH (30 mL). The aqueous solution was washed with ethyl acetate (100 mL) and the organics were discarded. The aqueous layer was acidified by the addition of concentrated hydrochloric acid (20 mL), resulting in the formation of a white suspension. The mixture was extracted with ethyl acetate (3×200 mL). The combined organics were washed with brine, dried over Na 2 SO 4 , filtered and evaporated to provide 2-(2-bromo-3-chloro-6-fluoro-phenyl)acetic acid (8.0 g, 49%) as a white solid.

[0510]

[0511] 1 H NMR (400 MHz, DMSO-d6)δ H :12.79(br.s,1H),7.67-7.59(m,1H),7.39-7.31(m,1H),3.82(s,2H).

[0512] 1.3 2-(2-Bromo-3-chloro-6-fluoro-phenyl)-N-methyl-acetohydrazide

[0513] To a stirred solution of 2-(2-bromo-3-chloro-6-fluoro-phenyl)acetic acid (2.0 g, 7.5 mmol) in dichloromethane (20 ml) at 0°C was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride [EDC.HCl] (1.4 g, 9.0 mmol) followed by dropwise addition of methylhydrazine (0.4 ml, 7.5 mmol). The temperature of the reaction mixture was maintained at 0°C for 3 h. The reaction was then quenched with water and extracted into dichloromethane. The organics were separated, washed with brine and dried over Na2SO4. Concentration under reduced pressure gave crude 2-(2-bromo-3-chloro-6-fluoro-phenyl)-N-methyl-acetohydrazide (1.8 g, 81%) which was used in the next step without further purification.

[0514]

[0515] 1 H NMR (400 MHz, DMSO-d6)δ H :7.59(dd,J=8.9 and 5.4,1H),7.30(t,J=8.9,1H),4.91(s,2H),4.10(br.s,2H),3.02(s,3H).

[0516] 1.4 2-{[2-(2-bromo-3-chloro-6-fluoro-phenyl)-acetyl]-methyl-hydrazono}-propionic acid ethyl ester

[0517] To a stirred solution of 2-(2-bromo-3-chloro-6-fluoro-phenyl)-N-methyl-acetohydrazide (1.8 g, 6.09 mmol) in ethanol (5 ml) was added ethyl pyruvate (0.7 ml, 6.7 mmol) dropwise. The reaction was heated at 80 ° C for 4 h. The reaction mixture was then cooled to room temperature and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent, ethyl acetate / hexane gradient) to give the desired compound 2-{[2-(2-bromo-3-chloro-6-fluoro-phenyl)-acetyl]-methyl-hydrazono}-ethyl propionate (1.8 g, 75%) as an off-white solid.

[0518]

[0519] 1 H NMR (400MHz, CDCl3)δ H:7.40-7.35(m,1H),7.04-6.98(m,1H),4.32(q,J=7.1,2H),4.24(s,2H),3.41(s,3H),2.32(s,3H),1.36(t,J=7.1,3H).

[0520] 1.5 4-(2-bromo-3-chloro-6-fluoro-phenyl)-5-hydroxy-2,6-dimethyl-pyridazin-3-one 2-{[2-(2-bromo-3-chloro-6-fluoro-phenyl)-acetyl]-methyl-hydrazono}-propionic acid ethyl ester (500mg, 1.27mmol) was dissolved in acetonitrile (2.5ml) and treated with 1,8-diazabicyclo[5.4.0]undec-7-ene[DBU](0.47ml, 3.2mmol). The mixture was heated to 125°C for 1h using microwave radiation. The reaction mixture was then evaporated under reduced pressure. The residue was dissolved in water and acidified to pH 1 with 2N hydrochloric acid. The mixture was extracted with DCM, the organics were separated and washed with brine solution. The organic solution was dried over Na2SO4 and concentrated under reduced pressure to give a crude product. The crude product was purified by silica gel column chromatography (eluent, ethyl acetate / hexane gradient) to give 4-(2-bromo-3-chloro-6-fluoro-phenyl)-5-hydroxy-2,6-dimethyl-pyridazin-3-one (340 mg, 77.1%) as an off-white solid.

[0521] 1 H NMR (400 MHz, DMSO-d6)δ H :11.01(s,1H),7.77-7.73(m,1H),7.39(t,J=8.7,1H),3.58(s,3H),2.24(s,3H).

[0522] 1.6 2-Methylpropionic acid [5-(2-bromo-3-chloro-6-fluoro-phenyl)-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester

[0523] To a stirred solution of 4-(2-bromo-3-chloro-6-fluoro-phenyl)-5-hydroxy-2,6-dimethyl-pyridazin-3-one (1.4 g, 4.02 mmol) in dichloromethane (32 ml) at room temperature were added triethylamine (1.1 ml, 8.06 mmol), 4-(dimethylamino)pyridine [DMAP] (49 mg, 0.40 mmol) and isobutyryl chloride (0.6 ml, 4.83 mmol).

[0524] Once judged to be complete, the reaction is diluted with dichloromethane and water. The organic layer is separated, dried over Na2SO4 and concentrated under reduced pressure to give a crude product. The crude product is purified by silica gel column chromatography (eluent, ethyl acetate / hexane gradient) to give 2-methylpropionic acid [5-(2-bromo-3-chloro-6-fluoro-phenyl)-1,3-dimethyl-6-oxo-pyridazine-4-yl] ester (1.47 g, 87%).

[0525]

[0526] 1 H NMR (400MHz, CDCl3)δ H :7.51-7.47(m,1H),7.10-7.05(m,1H),3.82(s,3H),2.60-2.55(m,1H),2.25(s,3H),1.02-0.98(m,6H).

[0527] 1.7 4-[3-Chloro-6-fluoro-2-[(E)-2-(4-phenylphenyl)vinyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-2.027)

[0528] 2-Methylpropionic acid [5-(2-bromo-3-chloro-6-fluoro-phenyl)-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (0.54 g, 1.3 mmol), K2CO3 (0.55 g, 3.9 mmol), trans-2-(4-phenylphenyl)vinylboronic acid (0.44 g, 2.00 mmol), PdCl2(dppf).DCM (53 mg, 0.065 mmol), 1,4-dioxane (13 ml) and H2O (3.3 mL) were combined in a 20 mL microwave vial and then heated at 140 °C under microwave irradiation for 30 min.

[0529] The reaction mixture is concentrated in a vacuum to remove 1,4-dioxanes, then distributed between 2N HCl (aqueous) and DCM. Separation of organic layer and extraction of aqueous layer with DCM (x2) of other parts. The organic matter merged is concentrated in a vacuum to give a crude residue, which is purified by silica gel column chromatography (eluent, ethyl acetate / hexane gradient) to give 4-[3-chloro-6-fluoro-2-[(E)-2-(4-phenylphenyl) vinyl] phenyl]-5-hydroxy-2,6-dimethyl-pyridazine-3-one (343mg, 53%, A-2.027) in yellow foam.

[0530] 1H NMR (400 MHz, chloroform) δ = 7.59-7.33 (m, 10H), 7.07 (t, J = 8.6 Hz, 1H), 7.01 (d, J = 16.4 Hz, 1H), 6.70 (d, J = 16.5 Hz, 1H), 5.63 (s, 1H), 3.73 (s, 3H), 2.28 (s, 3H)

[0531] 1.8 4-(3-Chloro-6-fluoro-2-phenylethyl-phenyl)-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-1.027)

[0532] To a 10 mL round bottom flask was added 5% Pd / C (73 mg, 0.034 mmol) followed by a solution of 4-[3-chloro-6-fluoro-2-[(E)-2-(4-phenylphenyl)vinyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (308 mg, 0.69 mmol) in 10:1 (v / v) DCM / MeOH (4 mL). B2(OH)4 (325 mg, 3.45 mmol) was then added and the reaction mixture was stirred at room temperature overnight.

[0533] The reaction mixture was then passed through Filtered, eluted with 10: 1 (v / v) DCM / MeOH. The filtrate is dried and loaded on silica and purified by silica gel column chromatography (eluent, ethyl acetate / hexane gradient) to give 4-[3-chloro-6-fluoro-2-[2-(4-phenylphenyl)ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazine-3-one (299 mg, 97% yield, A-1.027) as a yellow oil, which solidifies when standing.

[0534] 1 H NMR (400 MHz, chloroform) δ = 7.57-7.52 (m, 2H), 7.50-7.40 (m, 5H), 7.37-7.30 (m, 1H), 7.07 (d, J = 8.2 Hz, 2H), 7.02 (t, J = 8.6 Hz, 1H), 5.47 (s, 1H), 3.75 (s, 3H), 2.88-2.80 (m, 3H), 2.27 (s, 3H)

[0535] Example 2 Preparation of 4-[2-[6-chloro-3-fluoro-2-(5-hydroxy-2,6-dimethyl-3-oxo-pyridazin-4-yl)phenyl]ethyl]benzonitrile (A-1.036)

[0536]

[0537] 2.1 2-Methylpropionic acid [5-[3-chloro-2-[(E)-2-(4-cyanophenyl)vinyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (4.036)

[0538] 2-Methylpropanoic acid [5-(2-bromo-3-chloro-6-fluoro-phenyl)-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (1.10 g, 2.63 mmol) [prepared as described in Example 1] and chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (68 mg, 0.13 mmol) were combined in degassed toluene (12 mL). 4-Vinylbenzonitrile (408 mg, 3.16 mmol) and Hunig's base (0.92 mL, 5.27 mmol) were then added and the reaction mixture was heated to 95° C. for 2.5 h.

[0539] The reaction mixture was cooled to room temperature, then diluted with dichloromethane and filtered through celite, washed with additional dichloromethane. The filtrate was concentrated in vacuo and then purified by silica gel column chromatography (eluent, ethyl acetate / hexane gradient) to give 2-methylpropanoic acid [5-[3-chloro-2-[(E)-2-(4-cyanophenyl)vinyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (781 mg, 64% yield, A-4.036) as a white solid

[0540] 1 H NMR (400MHz, chloroform) δ=7.62-7.55(m,2H),7.45(dd,J=5.0,8.5Hz,1H),7.45-7.40(m,1H),7.13(d,J=16.5Hz,1H),7.05(t,J=8.5Hz ,1H),6.68(d,J=16.5Hz,1H),3.69(s,3H),2.65(spt,J=7.0Hz,1H),2.23(s,3H),1.11(d,J=7.0Hz,3H),1.07(d,J=7.0Hz,3H).

[0541] 2.2 2-Methylpropionic acid [5-[3-chloro-2-[2-(4-cyanophenyl)ethyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (A-3.036)

[0542] 2-Methylpropanoic acid [5-[3-chloro-2-[(E)-2-(4-cyanophenyl)vinyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (900 mg, 1.93 mmol) was subjected to catalytic hydrogenation under 4 bar H2 in EtOAc (20 mL) over 5% Pd / C (50% wet) catalyst (0.82 g).

[0543] After 1.5 h, LC / MS showed complete reaction. The reaction mixture was purified by Filter through a pad of Celite® and wash with ethyl acetate. The filtrate is concentrated in vacuo to give a crude residue.

[0544] The residue was adsorbed onto silica and purified by silica gel column chromatography (eluent, ethyl acetate / hexanes gradient) to give 2-methylpropanoic acid [5-[3-chloro-2-[2-(4-cyanophenyl)ethyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (800 mg, 81% yield, A-3.036) as a white solid.

[0545] 1 H NMR (400MHz, chloroform) δ = 7.56-7.51 (m, 2H), 7.42 (dd, J = 5.2, 8.9Hz, 1H), 7.26-7.21 (m, 2H), 7.00 (t, J = 8.9Hz, 1H), 3.84 (s, 3H), 3.02-2.9 2(m,1H),2.91-2.80(m,2H),2.75-2.65(m,1H),2.54(spt,J=7.0Hz,1H),2.25(s,3H),0.98(d,J=7.0Hz,3H),0.95(d,J=7.0Hz,3H).

[0546] 2.3 4-[2-[6-chloro-3-fluoro-2-(5-hydroxy-2,6-dimethyl-3-oxo-pyridazin-4-yl)phenyl]ethyl]benzonitrile (A-1.036)

[0547] 2-Methylpropanoic acid [[5-[3-chloro-2-[2-(4-cyanophenyl)ethyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (400 mg, 0.855 mmol) was dissolved in ethanol (6 mL). The mixture was treated with a solution of lithium hydroxide (108 mg, 2.56 mmol) in water (2 mL). The reaction was stirred at room temperature for 2 h.

[0548] The reaction mixture was concentrated in vacuo to remove ethanol. The remaining aqueous solution was diluted with water (15 mL), then acidified to approximately pH 3 with 2M HCl, and extracted with DCM (3×10 mL). The combined organics were dried over MgSO 4 , filtered, and concentrated in vacuo to provide a crude product.

[0549] The crude product was purified by silica gel column chromatography (eluent, ethyl acetate / hexane gradient) to give 4-[2-[6-chloro-3-fluoro-2-(5-hydroxy-2,6-dimethyl-3-oxo-pyridazin-4-yl)phenyl]ethyl]benzonitrile (83 mg, 91% yield, A-1.036) as a white solid.

[0550] 1 H NMR (400MHz, CDCl3) δppm7.46-7.51(m,2H)7.26-7.31(m,1H)7.08(d,J=8.19Hz,2H)6.86(t,J=8.50Hz,1H)3.63(s,3H)2.61-2.77(m,4H)2.24(s,3H).

[0551] Example 4 Preparation of 4-[2-[6-chloro-3-fluoro-2-(5-hydroxy-2,6-dimethyl-3-oxo-pyridazin-4-yl)phenyl]ethyl]-N-ethyl-2-fluoro-N-methyl-benzamide (A-1.028)

[0552]

[0553] 4.1 2-Methylpropanoic acid [5-[3-chloro-6-fluoro-2-[(E)-2-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborol-2-yl)vinyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester

[0554] 2-Methyl-propionic acid [5-(2-bromo-3-chloro-6-fluoro-phenyl)-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (5.00 g, 11.97 mmol, 1.0 eq), 6-methyl-2-vinyl-1,3,6,2-dioxazaboroctane-4,8-dione (2.63 g, 14.36 mmol, 1.2 eq) and chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (307 mg, 0.60 mmol, 0.05 eq) were charged into a 250 ml round bottom flask equipped with a condenser, a stirring bar and a nitrogen bubbler. THF (100 mL) was added followed by N,N-diisopropylethylamine (4.2 mL, 23.94 mmol, 2.0 eq) against a nitrogen stream and the mixture was heated to reflux for 3 h.

[0555] The reaction mixture was cooled to room temperature and then diluted in DCM and washed with Filter and wash with additional portions of DCM. The eluent is then concentrated to dryness.

[0556] The crude product was purified by flash column chromatography to give [5-[3-chloro-6-fluoro-2-[(E)-2-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborol-2-yl)vinyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] 2-methylpropanoate (5.91 g, 11.4 mmol, 95% yield) as an off-white solid.

[0557] 1 H NMR (400MHz, DMSO-d6) δ=7.63(dd,J=5.1,8.9Hz,1H),7.31(t,J=8.9Hz,1H),6.65(d,J=18.3Hz,1H),5.68(d,J=18.3Hz,1H),4.24(dd,J =11.9,17.2Hz,2H),3.95-3.83(m,2H),3.70(s,3H),2.66(spt,J=7.0Hz,1H),2.16(s,3H),0.90(d,J=7.0Hz,3H),0.89(d,J=7.0Hz,3H)

[0558] 4.2 2-Methylpropanoic acid [5-[3-chloro-2-[2-[4-[ethyl(methyl)carbamoyl]-3-fluoro-phenyl]ethyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (A-3.028)

[0559] 2-Methylpropanoic acid [5-[3-chloro-6-fluoro-2-[(E)-2-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborol-2-yl)vinyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl]ester (500 mg, 0.96 mmol), K3PO4 (886 mg, 3.85 mmol) and 1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex [PdCl2(dppf).DCM] (39 mg, 0.05 mmol) were added to a 20 mL microwave vial. THF (10 mL), 4-bromo-N-ethyl-2-fluoro-N-methyl-benzamide (500 mg, 1.92 mmol) and water (0.35 mL) were added, and the reaction mixture was heated to 100° C. under microwave irradiation for 2 hours.

[0560] The reaction mixture is concentrated in a vacuum to remove THF, then diluted with water (20mL) and DCM (20mL). Separate organic layer and extract aqueous layer with DCM (3 × 5mL). The organic matter merged is dried and concentrated in a vacuum to give a crude residue, which is purified by silica gel column chromatography (eluted with cyclohexane / ethyl acetate gradient) to give 2-methylpropionic acid [5-[3-chloro-2-[(E)-2-[4-[ethyl (methyl) carbamoyl]-3-fluoro-phenyl] vinyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazine-4-yl] ester (397mg, 76% yield, A-4.028) in off-white solid.

[0561] 2-Methylpropanoic acid [5-[3-chloro-2-[(E)-2-[4-[ethyl(methyl)carbamoyl]-3-fluoro-phenyl]vinyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (300 mg, 0.55 mmol) was subjected to catalytic hydrogenation under 3 bar H in EtOAc (6 mL) over 5% Pd / C (50% wet) catalyst (0.12 g).

[0562] After 5.5 h, LC / MS showed complete reaction. The reaction mixture was purified by Filter through a pad of Celite® and wash with ethyl acetate / methanol. The filtrate is concentrated in vacuo to give a crude residue.

[0563] The residue was adsorbed onto silica and purified by silica gel column chromatography (eluent, ethyl acetate / hexanes gradient) to give 2-methylpropanoic acid [5-[3-chloro-2-[2-[4-[ethyl(methyl)carbamoyl]-3-fluoro-phenyl]ethyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (285 mg, 95% yield, A-3.028) as a colorless gum.

[0564] [NMR of a mixture of rotamers] 1H NMR (400MHz, chloroform) δ=7.42(dd,J=5.1,8.9Hz,1H),[7.25(t,J=7.2Hz,0.5H),7.21(t,J=7.5Hz,0.5H)],6.99(t,J=8.9Hz,1H),6.96(dd,J=1.2,7.5Hz,1 H),[6.89(dd,J=1.2,6.9Hz,1H),6.86(dd,J=1.2,6.9Hz,1H)],3.85(s,3H ),[3.59(q,J=7.4Hz,1H),3.24(q,J=7.4Hz,1H)],[3.08(s,1.5H),2.90(br s,1.5H)],2.88-2.78(m,3H),2.75-2.64(m,1H),2.55(spt,J=7.0Hz,1H),2.26(s,3H),[1.2 3(t,J=7.2Hz,1.5H),1.10(t,J=7.2Hz,1.5H)],0.98(d,J=7.0Hz,3H),0.96(d,J=7.1Hz,3H)

[0565] 4.3 4-[2-[6-chloro-3-fluoro-2-(5-hydroxy-2,6-dimethyl-3-oxo-pyridazin-4-yl)phenyl]ethyl]-N-ethyl-2-fluoro-N-methyl-benzamide (A-1.028)

[0566] 2-Methylpropanoic acid [5-[3-chloro-2-[2-[4-[ethyl(methyl)carbamoyl]-3-fluoro-phenyl]ethyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (300 mg, 0.55 mmol) was dissolved in ethanol (3 mL). The mixture was treated with a solution of lithium hydroxide (69 mg, 1.65 mmol) in water (3 mL). The reaction was stirred at room temperature for 2 h.

[0567] The reaction mixture was concentrated in vacuo to remove ethanol. The remaining aqueous solution was diluted with water (15 mL), then acidified to approximately pH 3 with 2M HCl, and extracted with DCM (3×10 mL). The combined organics were dried and concentrated in vacuo to give the crude product.

[0568] The crude product was purified by silica gel column chromatography (eluent, DCM / methanol gradient) to give 4-[2-[6-chloro-3-fluoro-2-(5-hydroxy-2,6-dimethyl-3-oxo-pyridazin-4-yl)phenyl]ethyl]-N-ethyl-2-fluoro-N-methyl-benzamide (224 mg, 86% yield, A-1.028) as a white solid.

[0569] [NMR of a mixture of rotamers] 1 H NMR(400MHz,DMSO-d6)δ=10.86(br s,1H),7.55-7.49(m,1H),7.25-7.19(m,2H),6.95-6.89(m,2H),3.61(s,3H),3.46(q,J=7.1Hz,1H),3.12(q,J=7.1Hz, 1H), 2.95 (s, 1.5H), 2.78 (s, 1.5H), 2.78-2.63 (m, 4H), 2.26 (s, 3H), 1.11 (t, J = 7.1Hz, 1.5H), 1.00 (t, J = 7.1Hz, 1.5H).

[0570] Example 5 Preparation of 2-methylpropanoic acid [5-[3-chloro-2-[(E)-2-(4-cyclopropylphenyl)vinyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (A-4.038)

[0571]

[0572] 5.1 2-Methylpropionic acid [5-(3-chloro-6-fluoro-2-vinyl-phenyl)-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester

[0573] 2-Methylpropanoic acid [5-(2-bromo-3-chloro-6-fluoro-phenyl)-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (4.177 g, 10.00 mmol, 1.0 equiv) and tributyl(vinyl)stannane (4.384 mL, 15.00 mmol, 1.50 equiv) were dissolved in toluene (60.00 mL), and then 1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex [PdCl2(dppf).DCM] (408 mg, 0.50 mmol, 0.05 equiv) was added. The reaction mixture was heated at reflux overnight.

[0574] The reaction mixture was cooled to room temperature and then concentrated in vacuo. The crude product was then purified by flash column chromatography to give 2-methylpropanoic acid [5-(3-chloro-6-fluoro-2-vinyl-phenyl)-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (3.02 g, 83% yield) as an off-white solid.

[0575] 1H NMR (400MHz, CDCl3) δ = 7.40 (dd, J = 5.1, 8.7Hz, 1H), 6.99 (t, J = 8.7Hz, 1H), 6.65 (dd, J = 11.6, 17.6Hz, 1H), 5.37 -5.30(m,2H),3.79(s,3H),2.59(spt,J=7.0Hz,1H),2.23(s,3H),1.04(d,J=7.0Hz,4H),1.03(d,J=7.0Hz,1H)

[0576] 5.2 2-Methylpropionic acid [5-[3-chloro-2-[(E)-2-(4-cyclopropylphenyl)vinyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (A-4.038)

[0577] A stirred mixture of 2-methylpropanoic acid [5-(3-chloro-6-fluoro-2-vinyl-phenyl)-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (300 mg, 1.0 equiv), chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (21 mg, 0.05 equiv), 1-bromo-4-cyclopropylbenzene (243 mg, 1.5 equiv) and N,N-diisopropylethylamine (0.29 mL, 2.0 equiv) in toluene (5 mL) under nitrogen was heated at reflux for 3 h.

[0578] The reaction mixture was cooled to room temperature before it was diluted with DCM and filtered through a pad of celite, eluting with further portions of DCM. The filtrate was concentrated in vacuo to give the crude product.

[0579] The crude product was purified by flash column chromatography to give 2-methylpropanoic acid [5-[3-chloro-2-[(E)-2-(4-cyclopropylphenyl)vinyl]-6-fluoro-phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (285 mg, 72% yield) as a light yellow gum.

[0580] 1H NMR (400MHz, CDCl3) δ = 7.41 (dd, J = 5.1, 8.9Hz, 1H), 7.26-7.22 (m, 2H), 7.02-6.98 (m ,2H),6.99(t,J=8.9Hz,1H),6.93(d,J=16.5Hz,1H),6.59(d,J=16.5Hz,1H),3.71(s, 3H), 2.62 (spt, J=7.0Hz, 1H), 2.19 (s, 3H), 1.87 (tt, J=5.0, 8.4Hz, 1H), 1.07 (d, J=7. 0Hz, 3H), 1.06 (d, J = 7.0Hz, 1H), 0.99-0.93 (m, J = 2.0, 8.4Hz, 2H), 0.73-0.64 (m, 2H).

[0581] Example 6 Preparation of 4-[3-chloro-6-fluoro-2-[2-(4-methylsulfanylphenyl)ethyl]-phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-1.039)

[0582]

[0583] 6.1 2-Methylpropanoic acid [5-[3-chloro-6-fluoro-2-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester

[0584] The oven-dried round-bottom flask is then charged with Ir(COD)Cl2(299mg, 0.45mmol) and 4-diphenylphosphine butyl(diphenyl)phosphine (0380mg, 0.89mmol). The flask is evacuated and backfilled with nitrogen (x3), then THF (75mL) is added and the reaction is stirred at room temperature for 30min. Dropwise addition of 2-methylpropionic acid [5-(3-chloro-6-fluoro-2-vinyl-phenyl)-1,3-dimethyl-6-oxo-pyridazine-4-yl] ester [preparation as described in Example 4] (6.7g, 17.8mmol) in THF solution and the mixture is stirred for 10min, followed by dropwise addition of 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.02mL, 20.8mmol). The reaction is stirred at 60°C overnight.

[0585] After 24h, the reaction was cooled to room temperature and then concentrated in a vacuum. The crude product was purified by silica gel column chromatography (eluted with cyclohexane / ethyl acetate gradient) to give 2-methylpropionic acid [5-[3-chloro-6-fluoro-2-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)ethyl]phenyl]-1,3-dimethyl-6-oxo-pyridazine-4-yl] ester (4.50g, 51% yield) as a yellow solid.

[0586] 1 H NMR (500MHz, chloroform) δ = 7.35 (dd, J = 5.2, 8.9Hz, 1H), 6.90 (t, J = 8.6Hz, 1H), 3.81 (s, 3H), 2.59 (t, J = 8.5Hz, 2H), 2.53 (sp t,J=7.0Hz,1H),2.24(s,3H),1.32-1.16(m,12H),1.08-1.00(m,2H),0.98(d,J=7.0Hz,3H),0.94(d,J=7.0Hz,3H).

[0587] 6.2 4-[3-Chloro-6-fluoro-2-[2-(4-methylsulfanylphenyl)ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-1.039)

[0588] 2-Methylpropanoic acid [5-[3-chloro-6-fluoro-2-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl]ester (100 mg, 0.20 mmol), 1-bromo-4-methylsulfanyl-benzene (62 mg, 0.30 mmol), chloro(2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (24 mg, 0.03 mmol), K2CO3 (84 mg, 0.61 mmol), 1,4-dioxane (2 mL) and water (0.2 mL) were combined in a 5 mL microwave vial. The reaction mixture was then heated at 140° C. for 90 minutes under microwave irradiation.

[0589] The reaction mixture was cooled to room temperature, then diluted with water (10 mL), acidified with 2M HCl to approximately pH 3 and extracted with DCM (4x). The combined organics were concentrated in vacuo to give the crude product, which was purified by mass-directed reverse phase HPLC to afford 4-[3-chloro-6-fluoro-2-[2-(4-methylsulfanylphenyl)ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (22 mg, 22% yield, A-1.039) as a white solid.

[0590] 1 H NMR (400 MHz, chloroform) δ = 7.46-7.39 (m, 3H), 7.12 (d, J = 8.0 Hz, 2H), 6.98 (t, J = 8.6 Hz, 1H), 6.90 (d, J = 8.0 Hz, 2H), 3.73 (s, 3H), 2.84-2.64 (m, 4H), 2.45 (s, 3H), 2.29 (s, 3H).

[0591] Example 7 Preparation of 4-[3-chloro-6-fluoro-2-[2-[4-(methylsulfanylmethyl)phenyl]ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-1.388)

[0592]

[0593] 7.1 4-[3-Chloro-6-fluoro-2-[(E)-2-[4-(methylsulfanylmethyl)phenyl]vinyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one

[0594] 2-Methylpropanoic acid [5-[3-chloro-6-fluoro-2-[(E)-2-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborol-2-yl)vinyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl]ester (500 mg, 0.96 mmol), 1-bromo-4-(methylsulfanylmethyl)benzene (324 mg, 1.44 mmol), 1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex [PdCl2(dppf).DCM] (41 mg, 0.05 mmol) and potassium carbonate (417 mg, 2.89 mmol) were added to a 10-20 ml microwave vial under nitrogen atmosphere. Degassed acetonitrile (11.5 mL) and water (2.9 mL) were added and the mixture was heated to 150° C. under microwave irradiation for 20 min.

[0595] The reaction mixture is concentrated to dryness. The residue is treated with water (20ml), and the aqueous phase is acidified to pH 3 by adding 2M HCl, resulting in the formation of a precipitate. DCM (20ml) is added to dissolve the precipitate. Saline (20ml) is added and phase separation is performed. The aqueous phase is extracted with the DCM of two other parts, and then the organic extracts combined are dried and directly concentrated onto silica. The crude material is purified by automatic silica gel flash chromatography (eluted with cyclohexane / ethyl acetate gradient) to give 4- [3- chloro- 6- fluoro- 2- [(E) -2- [4- (methylsulfanyl methyl) phenyl] vinyl] phenyl] -5- hydroxy -2,6- dimethyl - pyridazine -3- ketone (341mg, 82% yield) in off-white solid.

[0596] 1 H NMR (500MHz, DMSO-d6) δ = 10.78 (brs, 1H), 7.60 (dd, J = 5.2, 8.7Hz, 1H), 7.30-7.24 (m, 5H), 6.93 (d,J=16.5Hz,1H),6.56(d,J=16.5Hz,1H),3.67(s,2H),3.54(s,3H),2.19(s,3H),1.94(s,3H)

[0597] 7.2 4-[3-Chloro-6-fluoro-2-[2-[4-(methylsulfanylmethyl)phenyl]ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-1.388)

[0598] To a solution of 4-[3-chloro-6-fluoro-2-[(E)-2-[4-(methylsulfanylmethyl)phenyl]vinyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (335 mg, 0.78 mmol) in tetrahydrofuran (12 ml) under nitrogen atmosphere was added N,N-diisopropylethylamine (1.08 ml, 6.20 mmol). The stirred reaction mixture was heated to 70°C and 2,4,6-triisopropylbenzenesulfonylhydrazide (2.06 g, 6.21 mmol) was added portionwise over 6 h and the mixture was then heated to reflux for 16 h. Additional N,N-diisopropylethylamine (0.68 ml, 3.89 mmol) was added to the reaction mixture followed by 2,4,6-triisopropylbenzenesulfonylhydrazide (1.29 g, 3.89 mmol) and the mixture was heated to reflux for an additional 6 h.

[0599] The reaction mixture was cooled to room temperature and then concentrated directly onto silica. The crude material was partially purified by automatic silica gel flash chromatography (eluted with cyclohexane / ethyl acetate gradient). The obtained material was further purified by mass-oriented reverse phase HPLC to obtain 4-[3-chloro-6-fluoro-2-[2-[4-(methylsulfanylmethyl)phenyl]ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazine-3-one (208 mg, 62% yield, A-1.388) as a white solid

[0600] 1 H NMR (400MHz, d6-DMSO), δ = 10.83 (s, 1H), 7.56-7.53 (m, 1H), 7.23-7.16 (m, 3H), 6.96 -6.94(d,2H),3.62(s,2H),3.60(s,3H),2.68-2.54(m,4H),2.26(s,3H),1.92(s,3H)

[0601] Example 8 4-[3-Chloro-6-fluoro-2-[2-[4-(1,2,4-triazol-1-yl)phenyl]ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-1.385)

[0602]

[0603] 8.1 Trifluoromethanesulfonic acid [4-(1,2,4-triazol-1-yl)phenyl] ester

[0604] 4-(1,2,4-triazol-1-yl)phenol (1.22 g, 7.57 mmol) was dissolved in dichloromethane (10 ml) under nitrogen and cooled to about 0°C. A solution of pyridine (1.22 ml, 15.1 mmol) in dichloromethane (5 ml) was added dropwise over about 2 min. The mixture was stirred for 5 minutes, then a solution of trifluoromethanesulfonic anhydride (1.53 ml, 9.08 mmol) in dichloromethane (5 ml) was added dropwise over about 2 minutes. The cooling was removed, and the reaction mixture was warmed to room temperature, then stirred at room temperature for 16 h.

[0605] The reaction was quenched by adding 2M aqueous HCl (20ml), and then the organic phase was separated. The aqueous phase was further extracted with dichloromethane (2×20ml). The combined organic matter was washed with water (20ml), dried, and then concentrated under reduced pressure to give a cream-colored solid. The crude material was purified by automatic silica gel flash chromatography (eluted with cyclohexane / ethyl acetate gradient) to give trifluoromethanesulfonic acid [4-(1,2,4-triazol-1-yl) phenyl] ester (2.02g, 91% yield) as a white solid.

[0606]

[0607] 1 H NMR (400 MHz, chloroform) δ = 8.59 (s, 1H), 8.14 (s, 1H), 7.86-7.78 (m, 2H), 7.50-7.41 (m, 2H).

[0608] 8.2 2-Methylpropionic acid [5-[3-chloro-6-fluoro-2-[(E)-2-[4-(1,2,4-triazol-1-yl)phenyl]vinyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester

[0609] 2-Methylpropanoic acid [5-[3-chloro-6-fluoro-2-[(E)-2-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborol-2-yl)vinyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (500 mg, 0.96 mmol), 1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex [PdCl2(dppf).DCM] (39 mg, 0.048 mmol), trifluoromethanesulfonic acid [4-(1,2,4-triazol-1-yl)phenyl] ester (367 mg, 1.25 mmol) and potassium phosphate (834 mg, 3.85 mmol) were added to a 10-20 ml microwave vial.

[0610] Tetrahydrofuran (10 ml) and water (0.5 ml) were added and the reaction mixture was then degassed by stirring under vacuum and then backfilled with nitrogen (X3).The reaction mixture was heated in a microwave at 120°C for 60 min under microwave irradiation.

[0611] The reaction mixture was passed through The mixture was filtered through a plug and washed with EtOAc and EtOH. The filtrate was concentrated under reduced pressure to give a brown gum (840 mg). The crude material was purified by automatic silica gel flash chromatography (eluted with cyclohexane / ethyl acetate gradient) to give a light yellow gum (389 mg). The purified material was dissolved in acetonitrile (10 ml) and washed with SiliCycle at room temperature. Thiol (SH) metal scavenger resin (365 mg) was treated. The suspension was stirred at room temperature for 3 h, then filtered to remove the resin, washing with additional acetonitrile. The filtrate was concentrated in vacuo to provide 2-methylpropanoic acid [5-[3-chloro-6-fluoro-2-[(E)-2-[4-(1,2,4-triazol-1-yl)phenyl]vinyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (361 mg, 73% yield) as a colorless gum.

[0612] 1 H NMR (400 MHz, chloroform) δppm8.55 (s, 1H), 8.11 (s, 1H), 7.60-7.66 (m, 2H), 7.42-7.53 (m, 3H), 7.01-7.10 (m, 2H), 6.69 (d, J = 16.5 Hz, 1H), 3.70 (s, 3H), 2.66 (spt, J = 7.0 Hz, 1H), 2.23 (s, 3H), 1.11 (d, J = 7.0 Hz, 1H), 1.08 (d, J = 7.1 Hz, 1H)

[0613] 8.3 2-Methylpropionic acid [5-[3-chloro-6-fluoro-2-[2-[4-(1,2,4-triazol-1-yl)phenyl]ethyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (A-3.385)

[0614] 2-Methylpropanoic acid [5-[3-chloro-6-fluoro-2-[(E)-2-[4-(1,2,4-triazol-1-yl)phenyl]vinyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (365 mg, 0.72 mmol) was subjected to catalytic hydrogenation under 3 bar H2 in EtOAc (10 mL) over 5% Pd / C (50% wet) catalyst (0.15 g) for 24 h.

[0615] The reaction mixture was passed through The mixture was stirred for 2 hours at 4 ℃ for 10 minutes.Then the mixture was stirred for 2 hours at 4 ℃ for 3 hours ...

[0616] 1H NMR (400 MHz, chloroform) δ = 8.51 (s, 1H), 8.09 (s, 1H), 7.55 (d, J = 8.2 Hz, 2H), 7.43 (dd, J = 5.2, 8.7 Hz, 1H), 7.27 (d, J = 8.2 Hz, 2H), 7.00 (t, J = 8.7 Hz, 1H), 3.84 (s, 3H), 2.97-2.80 (m, 3H), 2.79-2.67 (m, 1H), 2.55 (spt, J = 7.0 Hz, 1H), 2.25 (s, 3H), 0.98 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 1H)

[0617] 8.4 4-[3-Chloro-6-fluoro-2-[2-[4-(1,2,4-triazol-1-yl)phenyl]ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (A-1.385)

[0618] 2-Methylpropanoic acid [5-[3-chloro-6-fluoro-2-[2-[4-(1,2,4-triazol-1-yl)phenyl]ethyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl] ester (320 mg, 0.63 mmol) was stirred in ethanol (5 ml) at room temperature.

[0619] A solution of lithium hydroxide monohydrate (81 mg, 1.88 mmol) in water (2 ml) was added dropwise and the reaction was stirred at room temperature for 1 h.

[0620] The ethanol solvent is removed under reduced pressure, and the residue is then diluted with water (20ml). The aqueous phase is acidified to about pH 3-4 by adding 2M HCl (aqueous), and then it is extracted with EtOAc (3×10ml). The combined organic extracts are concentrated under reduced pressure to give a white solid (292mg). The crude residue is purified by automatic silica gel flash chromatography (eluted with cyclohexane / ethyl acetate and ethyl acetate / ethanol gradient), to obtain 4-[3-chloro-6-fluoro-2-[2-[4-(1,2,4-triazol-1-yl)phenyl]ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazine-3-one (A-1.365) (260mg, 94% yield) as a white solid.

[0621] 1H NMR (400 MHz, methanol), δ ppm 9.03 (s, 1H), 8.14 (s, 1H), 7.65-7.70 (m, 2H), 7.51 (dd, J = 5.2, 8.7 Hz, 1H), 7.20 (m, 2H), 7.11 (t, J = 8.7 Hz, 1H), 3.72 (s, 3H), 2.72-2.89 (m, 4H), 2.32 (s, 3H)

[0622] Example 9 4-[3-Cyclopropyl-6-fluoro-2-[2-(2-fluoro-4-pyridinyl)ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (C-1.013)

[0623] 2-Methylpropionic acid [5-[3-chloro-6-fluoro-2-[2-(2-fluoro-4-pyridyl)ethyl]phenyl]-1,3-dimethyl-6-oxo-pyridazin-4-yl]ester (250mg, 0.54mmol), potassium phosphate trihydrate (374mg, 1.62mmol) and RuPhosPd G2 (42mg, 0.05mmol) were charged into a 2-5ml microwave vial equipped with a stirring bar. The reaction vessel was evacuated and backfilled with nitrogen (X3). 1,4-dioxane (4ml) was added, followed by cyclopropylboronic acid (139mg, 1.62mmol) and water (1ml) (both degassed solvents). The mixture was then heated to 120°C for 1h under microwave irradiation.

[0624] The reaction was cooled to room temperature, then additional cyclopropylboronic acid (139 mg, 1.62 mmol) and RuPhos PdG2 (42 mg, 0.05 mmol) were added and the reaction was heated to 120°C for an additional 2.5 hours.

[0625] The reaction mixture was concentrated in vacuo to remove dioxane. The residue was diluted with water (20 ml) and DCM (20 mL), and the layers were separated. The aqueous phase was extracted with an additional portion of DCM (3 x 5 ml), and the combined organic extracts were then dried and concentrated to give a dark solid (331 mg).

[0626] The crude residue was purified by mass directed reverse phase HPLC to give 4-[3-cyclopropyl-6-fluoro-2-[2-(2-fluoro-4-pyridinyl)ethyl]phenyl]-5-hydroxy-2,6-dimethyl-pyridazin-3-one (C-1.013) as a white solid

[0627] 1H NMR (400 MHz, methanol) δ = 8.01 (d, J = 5.1 Hz, 1H), 7.13 (dd, J = 5.6, 8.3 Hz, 1H), 7.02-6.93 (m, 2H), 6.72 (br s, 1H), 3.72 (s, 3H), 3.02-2.75 (m, 4H), 2.32 (s, 3H), 1.97-1.87 (m, 1H), 1.02-0.89 (m, 2H), 0.74-0.61 (m, 2H)

[0628] Compounds A-1.023, A-1.024, A-1.025, A-1.026, A-1.027, A-1.028, A-1.029, A-1.030, A-1.031, A-1.032, A-1.033, A-1.03 were prepared using the general method described above. 4. A-1.035, A-1.036, A-1.037, A-1.038, A-1.039, A-1.040, A-1.041, A-1.042, A-1.043, A-1.044, A-2.027, A-2.030, A-2.037, A-3. 374, A-1.375, A-1.376, A-1.377, A-1.378, A-1.379, A-1.380, A-1.381, A-1.382, A-1.383, A-1.384, A-1.386, A-1.387, A-1.389, A-1.390, A-1.391 and A-1.392. Table 4 below shows the structures and NMR characterization data of these compounds.

[0629] Table 4 Preparation Examples of Compounds of Formula (I) The numbering system used to describe the positions of X and Y is shown for clarity only.

[0630]

[0631]

[0632]

[0633]

[0634]

[0635]

[0636]

[0637]

[0638]

[0639]

[0640]

[0641]

[0642]

[0643]

[0644]

[0645]

[0646]

[0647] B1 Post-emergence efficacy - Test 1

[0648] Seeds of various test species were sown in standard soil in pots: - Solanum nigrum (SOLNI), Amaranthus retoflexus (AMARE), Setaria faberi (SETFA), Echinochloa crus-galli (ECHCG), Ipomoea hederacea (IPOHE), Lolium perenne (LOLPE). After eight days of cultivation (post-emergence) in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity), the plants were sprayed with an aqueous spray solution derived from a formulation of technical grade active ingredient in acetone / water (50:50) solution containing 0.5% Tween 20 (polyoxyethylene sorbitan monolaurate, CAS RN9005-64-5). The compound was applied at 1000 g / ha. The test plants were then grown in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) and watered twice daily. After 13 days, the percentage of damage caused to the plants by the test was evaluated. The biological activity was assessed on a five-point scale (5 = 80%-100%; 4 = 60%-79%; 3 = 40-59%; 2 = 20-39%; 1 = 0-19%). A blank value in the table indicates that the compound was not tested on that species.

[0649] Table 5 Control of weed species by compounds of formula (I) after post-emergence application

[0650]

[0651] B2 Post-emergence efficacy - Test 2

[0652] Seeds of various test species were sown in standard soil in pots: - Solanum nigrum (SOLNI), Amaranthus retoflexus (AMARE), Setaria faberi (SETFA), Echinochloa crus-galli (ECHCG), Ipomoea hederacea (IPOHE), Lolium perenne (LOLPE). After eight days of cultivation (post-emergence) in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity), the plants were sprayed with an aqueous spray solution derived from a formulation of technical grade active ingredient in acetone / water (50:50) solution containing 0.5% Tween 20 (polyoxyethylene sorbitan monolaurate, CAS RN9005-64-5). The compound was applied at 250 g / ha. The test plants were then grown in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) and watered twice daily. After 13 days, the percentage of damage caused to the plants by the test was evaluated. The biological activity was assessed on a five-point scale (5 = 80%-100%; 4 = 60%-79%; 3 = 40-59%; 2 = 20-39%; 1 = 0-19%). A blank value in the table indicates that the compound was not tested on that species.

[0653] Table 6 Control of weed species by compounds of formula (I) after post-emergence application

[0654]

[0655]

[0656]

[0657] B3 Post-emergence efficacy - Test 3

[0658] Seeds of the following test species were sown in standard soil in pots: - Amaranthus retoflexus (AMARE), Setaria faberi (SETFA), Echinochloa crus-galli (ECHCG), Ipomoea hederacea (IPOHE), Zea Mays (ZEAMX), Abutilon theophrasti (ABUTH). After eight days of cultivation (post-emergence) in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 h light; 65% humidity), the plants were sprayed with an aqueous spray solution derived from a formulation of the technical grade active ingredient in an acetone / water (50:50) solution containing 0.5% Tween 20 (polyoxyethylene sorbitan monolaurate, CAS RN 9005-64-5). The compounds were applied at 250 g / ha. The test plants were then grown in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) and watered twice daily. After 13 days, the percentage of damage to the plants caused by the test was evaluated. The biological activity was evaluated on a five-point scale (5 = 80%-100%; 4 = 60%-79%; 3 = 40-59%; 2 = 20-39%; 1 = 0-19%). The blank value in the table indicates that the compound was not tested on that species.

[0659] Table 7 Control of weed species by compounds of formula (I) after post-emergence application

[0660]

[0661]

[0662] B4 Pre-emergence efficacy - Test 1

[0663] Seeds of various test species were sown in standard soil in pots: Solanum nigrum (SOLNI), Amaranthus retoflexus (AMARE), Setaria faberi (SETFA), Echinochloa crus-galli (ECHCG), Ipomoea hederacea (IPOHE), Lolium perenne (LOLPE). After one day of cultivation in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) (pre-emergence), the plants were sprayed with an aqueous spray solution derived from a formulation of the technical grade active ingredient in an acetone / water (50:50) solution containing 0.5% Tween 20 (polyoxyethylene sorbitan monolaurate, CAS RN9005-64-5). The compounds were applied at 1000 g / ha. The test plants were then grown in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) and watered twice a day. After 13 days, the percentage of damage caused to the plants by the test was evaluated. The biological activity was assessed on a five-point scale (5 = 80%-100%; 4 = 60%-79%; 3 = 40-59%; 2 = 20-39%; 1 = 0-19%). A blank value in the table indicates that that compound was not tested on that species.

[0664] Table 8 Control of weed species by compounds of formula (I) after pre-emergence application

[0665]

[0666] B5 Pre-emergence Efficacy - Test 2

[0667] Seeds of the following test species were sown in standard soil in pots: Solanum nigrum (SOLNI), Amaranthus retoflexus (AMARE), Setaria faberi (SETFA), Echinochloa crus-galli (ECHCG), Ipomoea hederacea (IPOHE), Lolium perenne (LOLPE). After one day of cultivation in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) (pre-emergence), the plants were sprayed with an aqueous spray solution derived from a formulation of the technical grade active ingredient in an acetone / water (50:50) solution containing 0.5% Tween 20 (polyoxyethylene sorbitan monolaurate, CAS RN9005-64-5). The compound was applied at 250 g / ha. The test plants were then grown in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) and watered twice a day. After 13 days, the percentage of damage caused to the plants by the test was evaluated. The biological activity was assessed on a five-point scale (5 = 80%-100%; 4 = 60%-79%; 3 = 40-59%; 2 = 20-39%; 1 = 0-19%). A blank value in the table indicates that that compound was not tested on that species.

[0668] Table 9 Control of weed species by compounds of formula (I) after pre-emergence application

[0669]

[0670]

[0671] B6 Pre-emergence Efficacy - Test 3

[0672] Seeds of the following test species were sown in standard soil in pots: Amaranthus retoflexus (AMARE), Setaria faberi (SETFA), Echinochloa crus-galli (ECHCG), Ipomoea hederacea (IPOHE), Zea Mays (ZEAMX), Abutilon theophrasti (ABUTH). After one day of cultivation in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) (pre-emergence), the plants were sprayed with an aqueous spray solution derived from a formulation of the technical grade active ingredient in an acetone / water (50:50) solution containing 0.5% Tween 20 (polyoxyethylene sorbitan monolaurate, CAS RN 9005-64-5). The compound was applied at 250 g / ha. The test plants were then grown in a greenhouse under controlled conditions (24°C / 16°C day / night; 14 hours of light; 65% humidity) and watered twice a day. After 13 days, the percentage of damage caused to the plants by the test was evaluated. The biological activity was assessed on a five-point scale (5 = 80%-100%; 4 = 60%-79%; 3 = 40-59%; 2 = 20-39%; 1 = 0-19%). A blank value in the table indicates that that compound was not tested on that species.

[0673] Table 10 Control of weed species by compounds of formula (I) after pre-emergence application

[0674]

Claims

1. A compound having formula (I) or a salt thereof, in, R 1 Selected from the group consisting of: C1-C4 alkyl; R 2 Selected from the group consisting of: C1-C6 alkyl; G is hydrogen or C(O)R 3 ; R 3 is isopropyl, tert-butyl, methyl, ethyl, propargyl, methoxy, ethoxy, or tert-butoxy; R 4 and R 5 are each independently hydrogen or C1-C4 alkyl; and, X and Y are each independently hydrogen or halogen; D is a substituted monocyclic heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, which is replaced on at least one ring carbon atom by R 8 and / or substituted on at least one ring nitrogen atom by R 9 replace; At least one R 8 Selected from the group consisting of: -C1-C3 alkyl-S(O) m -C1-C6 alkyl, -S(O)2NHC(O)C1-C3 alkyl, -S(O)2NR 4 R 5 、-C(O)OH、-C(O)OC1-C6alkyl、-C(O)NR 4 R 5 、-NR 4 C(O)NR 4 R 5 , C1-C6 alkylcarbonyl (C1-C6 alkyl) amino-, and a ring system selected from the group consisting of a phenyl ring, a 5-6 membered heteroaryl ring and a 3-6 membered heterocyclyl ring, wherein the ring system is surrounded by 0 to 5 R 16 replace; At least one R 9 Selected from the group consisting of: C3-C6-cycloalkyl; Any additional R 8 The substituent is selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 haloalkyl; m is an integer of 0 or 2; Each R 16 are independently halogen or C1-C6 alkyl; or D is occupied by at least one R 8 Substituted phenyl ring; and, W is in: "a" represents the point of attachment to the phenyl-pyridazinedione / phenyl-pyridazinone moiety, "b" indicates the point of attachment to ring D, R 10 , R 12 , R 14 and R 15 are each independently hydrogen; and R 11 and R 13 Each is hydrogen.

2. The compound according to claim 1, wherein X is in the ortho position relative to the pyridazinone / pyridazine-dione moiety.

3. The compound according to claim 1, wherein Relative to the -WD moiety, Y is in the ortho position.

4. The compound according to claim 1, wherein W is W1 and R 10 , R 11 , R 12 and R 13 Each is hydrogen.

5. The compound according to claim 1, wherein W is W2 and R 14 and R 15 Each is hydrogen.

6. A herbicidal composition comprising the herbicidal compound according to any one of claims 1 to 5, and an agriculturally acceptable formulation adjuvant.

7. The herbicidal composition according to claim 6, further comprising at least one additional pesticide.

8. The herbicidal composition according to claim 7, wherein The additional pesticide is a herbicide or a herbicide safener.

9. A method of controlling the growth of unwanted plants, the method comprising applying a compound of formula (I) as defined in any one of claims 1 to 5 or a herbicidal composition according to any one of claims 6 to 8 to the unwanted plants or the locus thereof.

10. Use of a compound of formula (I) as defined in any one of claims 1 to 5 as a herbicide.